Document:

Securities Purchase Agreement

 Exhibit 10.1 
 SECURITIES PURCHASE AGREEMENT 
 THIS SECURITIES PURCHASE AGREEMENT (the
“Agreement”), dated as of November 20, 2006, by and among Orchid Cellmark Inc., a Delaware corporation with headquarters located at 4390 US Route One, Princeton, NJ 08540 (the “Company”), and the investors
listed on the Schedule of Investors attached hereto as Exhibit A (individually, an “Investor” and collectively, the “Investors”). 
 BACKGROUND 
 A. The Company and each Investor are executing and delivering this Agreement in reliance
upon the exemption from registration afforded by Section 4(2) of the Securities Act of 1933, as amended (the “Securities Act”), and Rule 506 of Regulation D (“Regulation D”) as promulgated by the United
States Securities and Exchange Commission (the “SEC”) under the Securities Act. 
 B. Each Investor, severally and not
jointly, wishes to purchase, and the Company wishes to sell to each Investor, upon the terms and conditions stated in this Agreement that aggregate number of shares of the Common Stock, par value $.001 per share, of the Company (the “Common
Stock”), set forth opposite such Investor’s name in column two (2) on the Schedule of Investors in Exhibit A (which aggregate amount for all Investors together shall be 4,874,630 shares of Common Stock and shall
collectively be referred to herein as the “Common Shares”). 
 NOW, THEREFORE, IN CONSIDERATION of the mutual covenants
contained in this Agreement, and for other good and valuable consideration the receipt and adequacy of which are hereby acknowledged, the Company and the Investors agree as follows: 
 ARTICLE I 
 DEFINITIONS 
 1.1 Definitions. In addition to the terms defined elsewhere in this Agreement, the following terms have the meanings indicated: 
 “Affiliate” means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under
common control with a Person, as such terms are used in and construed under Rule 144 under the Securities Act. 
 “Agent” has the meaning set forth in Section 3.1(l). 
 “Agreement” has the meaning
set forth in the Preamble. 
 “Best Efforts” means the efforts that a prudent person desirous of achieving a result would
use in similar circumstances to ensure that such result is achieved as expeditiously as reasonably practical; provided, however, that an obligation to use Best Efforts under this Agreement does not require the Company to dispose of any or all
of its assets (other than cash) or make any change to its business, expend substantial funds or incur any other significant burden. 

 “Business Day” means any day other than Saturday, Sunday or other day on which
commercial banks in The City of New York are authorized or required by law to remain closed. 
 “Closing” means the closing
of the purchase and sale of the Common Shares pursuant to Section 2.1. 
 “Closing Date” means the date and time
of the Closing, which shall be November 21, 2006 or such other date and time as is mutually agreed to by the Company and the Investors. 
 “Closing Price” means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted on an Eligible Market or any other national securities
exchange, the closing price per share of the Common Stock for such date (or the nearest preceding date) on the primary Eligible Market or exchange on which the Common Stock is then listed or quoted; (b) if prices for the Common Stock are then
quoted on the OTC Bulletin Board, the closing bid price per share of the Common Stock for such date (or the nearest preceding date) so quoted; (c) if prices for the Common Stock are then reported in the “Pink Sheets” published by the
National Quotation Bureau Incorporated (or a similar organization or agency succeeding to its functions of reporting prices), the most recent closing bid price per share of the Common Stock so reported; or (d) in all other cases, the fair
market value of a share of Common Stock as determined by an independent appraiser selected in good faith by a majority-in-interest of the Investors. 
 “Common Shares” has the meaning set forth in the Preamble. 
 “Common
Stock” has the meaning set forth in the Preamble. 
 “Common Stock Equivalents” means, collectively, Options and
Convertible Securities. 
 “Company” has the meaning set forth in the Preamble. 
 “Company Counsel” means Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., counsel to the Company. 
 “Convertible Securities” means any stock or securities (other than Options) convertible into or exercisable or exchangeable for Common
Stock. 
 “Disclosure Materials” has the meaning set forth in Section 3.1(g). 
 “Effective Date” means the date that the Registration Statement is first declared effective by the SEC. 
 “Effectiveness Period” has the meaning set forth in Section 6.1(b). 
 “8-K Filing” has the meaning set forth in Section 4.4. 
 “Eligible Market” means any of the New York Stock Exchange, the American Stock Exchange, The Nasdaq Global Market or The Nasdaq Capital
Market. 
 “Environmental Laws” has the meaning set forth in Section 3.1(dd). 
  

 -2- 

 “Event” has the meaning set forth in Section 6.1(d). 
 “Event Payments” has the meaning set forth in Section 6.1(d). 
 “Exchange Act” means the Securities Exchange Act of 1934, as amended. 
 “Excluded Events” has the meaning set forth in Section 6.1(d). 
 “Excluded Investors” means Cowen and Company, LLC and its Affiliates. 
 “Filing Date” means the 45th day after the Closing Date. 
 “GAAP” has the meaning set forth in Section 3.1(g).

 “Hazardous Materials” has the meaning set forth in Section 3.1(dd). 
 “Indemnified Party” has the meaning set forth in Section 6.4(c). 
 “Indemnifying Party” has the meaning set forth in Section 6.4(c). 
 “Insolvent” has the meaning set forth in Section 3.1(h). 
 “Intellectual Property Rights” has the meaning set forth in Section 3.1(t). 
 “Investor” has the meaning set forth in the Preamble. 
 “Lien” means any lien, charge, claim, security interest, encumbrance, right of first refusal or other restriction. 
 “Losses” means any and all losses, claims, damages, liabilities, settlement costs and expenses, including, without limitation, reasonable attorneys’ fees. 
 “Material Adverse Effect” means (i) a material adverse effect on the results of operations, assets, business or financial condition
of the Company and the Subsidiaries, taken as a whole on a consolidated basis, or (ii) materially and adversely impair the Company’s ability to perform its obligations under any of the Transaction Documents, provided, that none of the
following alone shall be deemed, in and of itself, to constitute a Material Adverse Effect: (i) a change in the market price or trading volume of the Common Stock or (ii) changes in general economic conditions or changes affecting the
industry in which the Company operates generally (as opposed to Company-specific changes) so long as such changes do not have a materially disproportionate effect on the Company and its Subsidiaries taken as a whole. 
 “Material Permits” has the meaning set forth in Section 3.1(v). 
 “Options” means any outstanding rights, warrants or options to subscribe for or purchase Common Stock or Convertible Securities.

 “Person” means any individual or corporation, partnership, trust, incorporated or unincorporated association, joint
venture, limited liability company, or joint stock company. 
  

 -3- 

 “Proceeding” means an action, claim, suit, investigation or proceeding (including,
without limitation, or a partial proceeding, such as a deposition), whether commenced or threatened in writing. 
 “Prospectus” means the prospectus included in the Registration Statement (including, without limitation, a prospectus that includes any information previously omitted from a prospectus filed as part of an effective
registration statement in reliance upon Rule 430A promulgated under the Securities Act), as amended or supplemented by any prospectus supplement, with respect to the terms of the offering of any portion of the Registrable Securities covered by the
Registration Statement, and all other amendments and supplements to the Prospectus including post-effective amendments, and all material incorporated by reference or deemed to be incorporated by reference in such Prospectus. 
 “Registrable Securities” means the Common Shares issued pursuant to the Transaction Documents, together with any securities issued or
issuable upon any stock split, dividend or other distribution, recapitalization or similar event with respect to the foregoing. 
 “Registration Statement” means each registration statement required to be filed under Article VI, including (in each case) the Prospectus, amendments and supplements to such registration statement or Prospectus,
including pre- and post-effective amendments, all exhibits thereto, and all material incorporated by reference or deemed to be incorporated by reference in such registration statement. 
 “Regulation D” has the meaning set forth in the Preamble. 
 “Required Effectiveness Date” means (i) if the Registration Statement does not become subject to review by the SEC, the date which is the earliest of (a) ninety (90) days after the
Closing Date or (b) five (5) Trading Days after the Company receives notification from the SEC that the Registration Statement will not become subject to review and the Company fails to request to accelerate the effectiveness of the
Registration Statement, or (ii) if the Registration Statement becomes subject to review by the SEC, one hundred and twenty (120) days after the Closing Date. 
 “Rule 144,” “Rule 415,” and “Rule 424” means Rule 144, Rule 415 and Rule 424, respectively, promulgated by the SEC pursuant to the
Securities Act, as such Rules may be amended from time to time, or any similar rule or regulation hereafter adopted by the SEC having substantially the same effect as such Rule. 
 “SEC” has the meaning set forth in the Preamble. 
 “SEC Reports” has the meaning set forth in Section 3.1(g). 
 “Securities Act” has the meaning set forth in the Preamble. 
 “Shares” means shares of the
Company’s Common Stock. 
 “Short Sales” has the meaning set forth in Section 3.2(h). 
 “Subsidiary” means any direct or indirect subsidiary of the Company. 
  

 -4- 

 “Trading Day” means (a) any day on which the Common Stock is listed or quoted and
traded on its primary Trading Market, (b) if the Common Stock is not then listed or quoted and traded on any Eligible Market, then a day on which trading occurs on the The Nasdaq Global Market (or any successor thereto), or (c) if trading
ceases to occur on the The Nasdaq Global Market (or any successor thereto), any Business Day. 
 “Trading Market” means The
Nasdaq Global Market or any other Eligible Market, or any national securities exchange, market or trading or quotation facility on which the Common Stock is then listed or quoted. 
 “Transaction Documents” means this Agreement, the schedules and exhibits attached hereto, and the Transfer Agent Instructions.

 “Transfer Agent” means American Stock Transfer & Trust Company, or any successor transfer agent for the Company.

 “Transfer Agent Instructions” means, with respect to the Company, the Irrevocable Transfer Agent Instructions, in the
form of Exhibit E, executed by the Company and delivered to and acknowledged in writing by the Transfer Agent. 
 ARTICLE II

 PURCHASE AND SALE 
 2.1
Closing. Subject to the terms and conditions set forth in this Agreement, at the Closing the Company shall issue and sell to each Investor, and each Investor shall, severally and not jointly, purchase from the Company, such number of Common
Shares for the price set forth opposite such Investor’s name on Exhibit A hereto under the heading “Common Shares.” The date and time of the Closing and shall be 11:00 a.m., New York City Time, on the Closing Date. The
Closing shall take place at the offices of the Company’s Counsel. 
 2.2 Closing Deliveries. 
 (a) At the Closing, the Company shall deliver or cause to be delivered to each Investor the following: 
 (i) one or more stock certificates (or copies thereof provided by the Transfer Agent), free and clear of all restrictive and other legends (except as
expressly provided in Section 4.1(b) hereof), evidencing such number of Common Shares set forth opposite such Investor’s name on Exhibit A hereto under the heading “Common Shares,” registered in the name of
such Investor; 
 (ii) a legal opinion of Company Counsel, in the form of Exhibit C, executed by such counsel and delivered to
the Investors; 
 (iii) duly executed Transfer Agent Instructions acknowledged by the Transfer Agent; and 
  

 -5- 

 (iv) a copy of the “Notification Form: Listing of Additional Shares” submitted to The NASDAQ
Stock Market LLC covering all of the Registrable Securities. 
 (b) At the Closing, each Investor shall deliver or cause to be delivered to
the Company the purchase price set forth opposite such Investor’s name on Exhibit A hereto under the heading “Purchase Price” in United States dollars and in immediately available funds, by wire transfer to an account
designated in writing to such Investor by the Company for such purpose. 
 ARTICLE III 
 REPRESENTATIONS AND WARRANTIES 
 3.1 Representations and Warranties of the
Company. The Company hereby represents and warrants to the Investors as follows: 
 (a) Subsidiaries. Each of the Company’s
Subsidiaries that is a “significant subsidiary” under Rule 1-02(w) of Regulation S-X is listed in Schedule 3.1(a) hereto (collectively, the “Material Subsidiaries”). Except as disclosed in Schedule 3.1(a)
hereto or in the SEC Reports, the Company owns, directly or indirectly, all of the capital stock or comparable equity interests of each Material Subsidiary free and clear of any Lien and all the issued and outstanding shares of capital stock or
comparable equity interest of each Material Subsidiary are validly issued and are fully paid, non-assessable and free of preemptive and similar rights. 
 (b) Organization and Qualification. Each of the Company and the Subsidiaries is an entity duly organized, validly existing and in good standing under the laws of the jurisdiction of its incorporation or
organization (as applicable), with the requisite legal authority to own and use its properties and assets and to carry on its business as currently conducted. Neither the Company nor any Material Subsidiary is in violation of any of the provisions
of its respective certificate or articles of incorporation, bylaws or other organizational or charter documents. Each of the Company and the Material Subsidiaries is duly qualified to do business and is in good standing as a foreign corporation or
other entity in each jurisdiction in which the nature of the business conducted or property owned by it makes such qualification necessary, except where the failure to be so qualified or in good standing, as the case may be, would not, individually
or in the aggregate, have a Material Adverse Effect. 
 (c) Authorization; Enforcement. The Company has the requisite corporate
authority to enter into and to consummate the transactions contemplated by each of the Transaction Documents to which it is a party and otherwise to carry out its obligations hereunder and thereunder. The execution and delivery by the Company of
each of the Transaction Documents to which it is a party and the consummation by it of the transactions contemplated hereby and thereby have been duly authorized by all necessary action on the part of the Company and no further consent or action is
required by the Company, its Board of Directors or its stockholders. Each of the Transaction Documents to which it is a party has been (or upon delivery will be) duly executed by the Company and is, or when delivered in accordance with the terms
hereof, will constitute, the valid and binding obligation of the Company enforceable against the Company in accordance with its terms, except as may be limited by (i) applicable bankruptcy, insolvency, reorganization or other laws of general
application relating to or affecting the enforcement of creditors rights generally, and (ii) the effect of rules of law governing the availability of specific performance and other equitable remedies. 
  

 -6- 

 (d) No Conflicts. The execution, delivery and performance by the Company of the Transaction
Documents to which it is a party and the consummation by the Company of the transactions contemplated hereby and thereby do not, and will not, (i) conflict with or violate any provision of the Company’s or any Material Subsidiary’s
certificate or articles of incorporation, bylaws or other organizational or charter documents, (ii) conflict with, or constitute a default (or an event that with notice or lapse of time or both would become a default) under, or give to others
any rights of termination, amendment, acceleration or cancellation (with or without notice, lapse of time or both) of, any agreement, credit facility, debt or other instrument (evidencing a Company or Subsidiary debt or otherwise) or other
understanding to which the Company or any Material Subsidiary is a party or by which any property or asset of the Company or any Material Subsidiary is bound, or affected, except to the extent that such conflict, default, termination, amendment,
acceleration or cancellation right would not have a Material Adverse Effect, or (iii) result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or governmental authority to which
the Company or a Material Subsidiary is subject (including, assuming the accuracy of the representations and warranties of the Investors set forth in Section 3.2 hereof, federal and state securities laws and regulations and the rules and
regulations of any self-regulatory organization to which the Company or its securities are subject, including the primary Trading Market on which the Common Stock is traded), or by which any property or asset of the Company or a Material Subsidiary
is bound or affected, except to the extent that such violation would not have a Material Adverse Effect. 
 (e) The Common Shares. The
Common Shares are duly authorized and, when issued and paid for in accordance with the Transaction Documents, will be duly and validly issued, fully paid and nonassessable, free and clear of all Liens (other than those imposed by Investors) and will
not be subject to preemptive or similar rights of stockholders. Assuming the accuracy of the representations and warranties of the Investors set forth in Section 3.2 hereof at the time of issuance of the Common Shares, the offer,
issuance and sale of the Common Shares to the Investors pursuant to the Agreement are exempt from the registration requirements of the Securities Act. 
 (f) Capitalization. The aggregate number of shares and type of all authorized, issued and outstanding classes of capital stock, options and other securities of the Company (whether or not presently convertible
into or exercisable or exchangeable for shares of capital stock of the Company) is set forth in Schedule 3.1(f) hereto. All outstanding shares of capital stock of the Company are duly authorized, validly issued, fully paid and
nonassessable and have been issued in compliance in all material respects with all applicable securities laws. Except as disclosed in Schedule 3.1(f) hereto or in the SEC Reports, the Company did not have outstanding at November 20,
2006 any other options, warrants, script rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities, rights or obligations convertible into or exercisable or exchangeable for, and, other than the Transaction
Documents, has not entered into any agreement giving any Person any right to subscribe for or acquire, any shares of Common Stock, or securities or rights convertible or exchangeable into shares of Common Stock. Except as set forth on Schedule
3.1(f) hereto, and except for customary adjustments as a result of stock dividends, stock splits, combinations of shares, reorganizations, recapitalizations, reclassifications or other similar events, there are no anti-dilution or price
adjustment provisions contained in any security issued by the Company (or in any agreement providing rights to security holders) and the issuance and sale of the Common Shares will not obligate the Company to issue shares of Common Stock or other
securities to any Person (other than the Investors) and will not result in a right of any holder of Company 

  

 -7- 

 
securities to adjust the exercise, conversion, exchange or reset price under such securities. To the knowledge of the Company, except as disclosed in the SEC
Reports and any Schedules filed with the SEC pursuant to Rule 13d-1 of the Exchange Act by reporting persons or in Schedule 3.1(f) hereto, no Person or group of related Persons beneficially owns (as determined pursuant to Rule 13d-3 under the
Exchange Act), or has the right to acquire, by agreement with or by obligation binding upon the Company, beneficial ownership of in excess of 5% of the outstanding Common Stock. 
 (g) SEC Reports; Financial Statements. Except as disclosed in Schedule 3.1(g) or in the SEC Reports, the Company has filed all reports
required to be filed by it under the Exchange Act, including pursuant to Section 13(a) or 15(d) thereof, for the 12 months preceding the date hereof on a timely basis or has received a valid extension of such time of filing and has filed any
such SEC Reports prior to the expiration of any such extension and has filed all reports required to be filed by it under the Exchange Act, including pursuant to Section 13(a) or 15(d) thereof, for the two years preceding the date hereof. Such
reports required to be filed by the Company under the Exchange Act, including pursuant to Section 13(a) or 15(d) thereof, together with any materials filed or furnished by the Company under the Exchange Act, whether or not any such reports were
required being collectively referred to herein as the “SEC Reports” and, together with this Agreement and the Schedules to this Agreement, the “Disclosure Materials”. As of their respective dates, the SEC Reports
filed by the Company complied in all material respects with the requirements of the Securities Act and the Exchange Act and the rules and regulations of the SEC promulgated thereunder, and none of the SEC Reports, when filed by the Company,
contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading,
except to the extent that information contained in any SEC Report has been revised or superseded by a later filed SEC Report. Except as set forth in the SEC Reports, the financial statements of the Company included in the SEC Reports comply in all
material respects with applicable accounting requirements and the rules and regulations of the SEC with respect thereto as in effect at the time of filing except to the extent that information contained in any SEC Report has been revised or
superseded by a later filed SEC Report. Such financial statements have been prepared in accordance with United States generally accepted accounting principles applied on a consistent basis during the periods involved (“GAAP”),
except as may be otherwise specified in such financial statements, the notes thereto and except that unaudited financial statements may not contain all footnotes required by GAAP or may be condensed or summary statements, and fairly present in all
material respects the consolidated financial position of the Company and its consolidated subsidiaries as of and for the dates thereof and the results of operations and cash flows for the periods then ended, subject, in the case of unaudited
statements, to normal, year-end audit adjustments. All material agreements to which the Company or any Subsidiary is a party or to which the property or assets of the Company or any Subsidiary are subject are included as part of or identified in the
SEC Reports, to the extent such agreements are required to be included or identified pursuant to the rules and regulations of the SEC. 
 (h)
No Material Changes. Since the date of the latest audited financial statements included within the SEC Reports, except as disclosed in the SEC Reports, in press releases or other “public disclosures” as such term is defined in
Section 101(c) of Regulation FD of the Exchange Act or in Schedule 3.1(h) hereto, (i) there has been no event, occurrence or development that, individually or in the aggregate, has had or that would result in a Material Adverse
Effect, (ii) the Company has not incurred any material liabilities other than (A) trade payables and accrued 

  

 -8- 

 
expenses incurred in the ordinary course of business consistent with past practice and (B) liabilities not required to be reflected in the
Company’s financial statements pursuant to GAAP or required to be disclosed in filings made with the SEC, (iii) the Company has not altered its method of accounting or changed its auditors, except as disclosed in its SEC Reports,
(iv) the Company has not declared or made any dividend or distribution of cash or other property to its stockholders, in their capacities as such, or purchased, redeemed or made any agreements to purchase or redeem any shares of its capital
stock (except for repurchases by the Company of shares of capital stock held by employees, officers, directors, or consultants pursuant to an option of the Company to repurchase such shares upon the termination of employment or services), and
(v) the Company has not issued any equity securities to any officer, director or Affiliate, except pursuant to existing Company stock-based plans. The Company has not taken any steps to seek protection pursuant to any bankruptcy law nor does
the Company have any knowledge or reason to believe that its creditors intend to initiate involuntary bankruptcy proceedings or any actual knowledge of any fact which would reasonably lead a creditor to do so. The Company is not as of the date
hereof, and after giving effect to the transactions contemplated hereby to occur at the applicable Closing, will not be Insolvent (as defined below). For purposes of this Section 3.1(h), “Insolvent” means (i) the
present fair saleable value of the Company’s assets is less than the amount required to pay the Company’s total indebtedness, (ii) the Company is unable to pay its debts and liabilities, subordinated, contingent or otherwise, as such
debts and liabilities become absolute and matured, (iii) the Company intends to incur or believes that it will incur debts that would be beyond its ability to pay as such debts mature or (iv) the Company has unreasonably small capital with
which to conduct the business in which it is engaged for the current fiscal year as such business is now conducted and is proposed to be conducted. 
 (i) Absence of Litigation. Except as disclosed in the SEC Reports, there is no action, suit, claim, or proceeding, or, to the Company’s knowledge, inquiry or investigation, before or by any court, public board, government
agency, self-regulatory organization or body pending or, to the knowledge of the Company, threatened against or affecting the Company or any of its Material Subsidiaries that would, individually or in the aggregate, have a Material Adverse Effect.

 (j) Compliance. Except as described in Schedule 3.1(j) or as disclosed in the SEC Reports, neither the Company nor any
Material Subsidiary, except in each case as would not, individually or in the aggregate, have a Material Adverse Effect, (i) is in default under or in violation of (and no event has occurred that has not been waived that, with notice or lapse
of time or both, would result in a default by the Company or any Material Subsidiary under), nor has the Company or any Material Subsidiary received written notice of a claim that it is in default under or that it is in violation of, any indenture,
loan or credit agreement or any other agreement or instrument to which it is a party or by which it or any of its properties is bound (whether or not such default or violation has been waived), (ii) is in violation of any order of any court,
arbitrator or governmental body applicable to it, or (iii) is or has been in violation of any statute, rule or regulation of any governmental authority applicable to it. 
 (k) Title to Assets. The Company and the Subsidiaries have good and marketable title to all real property owned by them that is material to the
business of the Company and the Subsidiaries taken as a whole and good and marketable title to all personal property owned by them that is material to the business of the Company and the Subsidiaries taken as a whole, in each case free and clear of
all Liens, except for Liens that do not, individually or in the aggregate, have or 

  

 -9- 

 
result in a Material Adverse Effect. Any real property and facilities held under lease by the Company and the Material Subsidiaries are held by them under
valid, subsisting and enforceable leases of which the Company and the Material Subsidiaries are in material compliance. 
 (l) No General
Solicitation; Placement Agent’s Fees. Neither the Company, nor any of its Affiliates, nor any Person acting on its or their behalf, has engaged in any form of general solicitation or general advertising (within the meaning of
Regulation D) in connection with the offer or sale of the Common Shares. The Company shall be responsible for the payment of any placement agent’s fees, financial advisory fees, or brokers’ commission (other than for Persons engaged
by any Investor or its investment advisor) relating to or arising out of the issuance of the Common Shares pursuant to this Agreement. The Company shall pay, and hold each Investor harmless against, any liability, loss or expense (including, without
limitation, reasonable attorney’s fees and out-of-pocket expenses) arising in connection with any such claim for fees arising out of the issuance of the Common Shares pursuant to this Agreement. The Company acknowledges that is has engaged
Cowen and Company, LLC as its exclusive placement agent (the “Agent”) in connection with the sale of the Common Shares. Other than the Agent, the Company has not engaged any placement agent or other agent in connection with the sale
of the Common Shares. 
 (m) Private Placement. Neither the Company nor any of its Affiliates nor any Person acting on the
Company’s behalf has, directly or indirectly, at any time within the past six months, made any offer or sale of any security or solicitation of any offer to buy any security under circumstances that would (i) eliminate the availability of
the exemption from registration under Regulation D under the Securities Act in connection with the offer and sale by the Company of the Common Shares as contemplated hereby or (ii) cause the offering of the Common Shares pursuant to the
Transaction Documents to be integrated with prior offerings by the Company for purposes of any applicable law, regulation or stockholder approval provisions, including, without limitation, under the rules and regulations of any Trading Market. The
Company is not required to be registered as an “investment company” within the meaning of the Investment Company Act of 1940, as amended. The Company is not a United States real property holding corporation within the meaning of the
Foreign Investment in Real Property Tax Act of 1980. 
 (n) No Form S-3 Eligibility. The Company is not eligible to register the
Common Shares for resale by the Investors using Form S-3 promulgated under the Securities Act. 
 (o) Listing and Maintenance
Requirements. Except as disclosed in Schedule 3.1(o) or in the SEC Reports, the Company has not, in the twelve months preceding the date hereof, received notice (written or oral) from any Trading Market on which the Common Stock is or has
been listed or quoted to the effect that the Company is not in compliance with the listing or maintenance requirements of such Trading Market. The Company is in compliance with all such listing and maintenance requirements. 
 (p) Registration Rights. Except as disclosed in Schedule 3.1(p) or the SEC Reports, the Company has not granted or agreed to grant to any
Person any rights (including “piggy-back” registration rights) to have any securities of the Company registered with the SEC or any other governmental authority that have not been satisfied or waived. 
  

 -10- 

 (q) Application of Takeover Protections. Except as disclosed in Schedule 3.1(q) or in the
SEC Reports, there is no control share acquisition, business combination, poison pill (including any distribution under a rights agreement) or other similar anti-takeover provision under the Company’s charter documents or the laws of its state
of incorporation that is or could become applicable to any of the Investors as a result of the Investors and the Company fulfilling their obligations or exercising their rights under the Transaction Documents, including, without limitation, as a
result of the Company’s issuance of the Common Shares and the Investors’ ownership of the Common Shares. 
 (r) Disclosure.
The Company confirms that neither it nor any of its officers, directors or Affiliates, has provided any of the Investors (other than Excluded Investors) or their agents or counsel with any information that constitutes or might constitute material,
nonpublic information (other than the existence and terms of the issuance of Common Shares, as contemplated by this Agreement). The Company understands and confirms that each of the Investors will rely on the foregoing representations in effecting
transactions in securities of the Company (other than Excluded Investors). All disclosure provided by the Company to the Investors regarding the Company, its business and the transactions contemplated hereby, including the Schedules to this
Agreement, furnished by or on the behalf of the Company are true and correct in all material respects and do not contain any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements made
therein, in the light of the circumstances under which they were made, not misleading. To the Company’s knowledge, except for the transactions contemplated by this Agreement, no event or circumstance has occurred or information exists with
respect to the Company or any of its Subsidiaries or its or their business, properties, operations or financial conditions, which, under applicable law, rule or regulation, requires public disclosure or announcement by the Company but which has not
been so publicly announced or disclosed. The Company acknowledges and agrees that no Investor makes or has made any representations or warranties with respect to the transactions contemplated hereby other than those set forth in the Transaction
Documents. 
 (s) Acknowledgment Regarding Investors’ Purchase of Common Shares. Based upon the assumption that the transactions
contemplated by this Agreement are consummated in all material respects in conformity with the Transaction Documents, the Company acknowledges and agrees that each of the Investors (other than Excluded Investors) is acting solely in the capacity of
an arm’s length purchaser with respect to the Transaction Documents and the transactions contemplated hereby and thereby. The Company further acknowledges that no Investor (other than Excluded Investors) is acting as a financial advisor or
fiduciary of the Company (or in any similar capacity) with respect to this Agreement and the transactions contemplated hereby and any advice given by any Investor (other than Excluded Investors) or any of their respective representatives or agents
in connection with the Transaction Documents and the transactions contemplated hereby and thereby is merely incidental to the Investors’ purchase of the Common Shares. The Company further represents to each Investor that the Company’s
decision to enter into this Agreement has been based solely on the independent evaluation of the transactions contemplated hereby by the Company and its representatives. 
 (t) Patents and Trademarks. To the knowledge of the Company, the Company and its Material Subsidiaries own, or possess adequate rights or licenses to use, all trademarks, trade names, service marks, service
mark registrations, service names, patents, patent rights, copyrights, 

  

 -11- 

 
inventions, trade secrets and other intellectual property rights (“Intellectual Property Rights”) necessary to conduct their respective
businesses now conducted unless described in the SEC Reports, where the failure to so own or possess would have a Material Adverse Effect. Except as set forth in Schedule 3.1(t) or in the SEC Reports, none of the patents or registered
trademarks of the Company that are included in the Company’s Intellectual Property Rights have expired or terminated, or are expected to expire or terminate, within two years from the date of this Agreement. Except as set forth in Schedule
3.1(t), the Company has not received any written notice that the Intellectual Property Rights used by the Company or any Subsidiary violates or infringes upon the patents or registered trademarks of others that would individually, or in the
aggregate, have a Material Adverse Effect. Except as disclosed in the SEC Reports, or as set forth in Schedule 3.1(t), there is no claim, action or proceeding being made or brought, or to the knowledge of the Company, being threatened,
against the Company or its Material Subsidiaries regarding its Intellectual Property Rights that would individually, or in the aggregate, have a Material Adverse Effect. 
 (u) Insurance. The Company and the Material Subsidiaries are insured by insurers of recognized financial responsibility against such losses and risks and in such amounts as are prudent and customary in the
businesses and location in which the Company and the Material Subsidiaries are engaged. 
 (v) Regulatory Permits. The Company and the
Material Subsidiaries possess all certificates, authorizations and permits issued by the appropriate federal, state, local or foreign regulatory authorities necessary to conduct their respective businesses as described in the SEC Reports, except
where the failure to possess such permits does not, individually or in the aggregate, have a Material Adverse Effect (“Material Permits”), and neither the Company nor any Material Subsidiary has received any written notice of
proceedings relating to the revocation or modification of any Material Permit. 
 (w) Transactions With Affiliates and Employees.
Except as set forth or incorporated by reference in the Company’s SEC Reports, none of the officers or directors of the Company and, to the knowledge of the Company, none of the employees of the Company is presently a party to any transaction
with the Company or any of its Subsidiaries that would be required to be reported on Form 10-K (other than transactions for agreements relating to ordinary course services as employees, officers or directors or the grant of stock options, restricted
stock, stock or related rights, pursuant to compensation plans described in the SEC Reports in connection with such service), including any contract, agreement or other arrangement providing for the furnishing of services to or by, providing for
rental of real or personal property to or from, or otherwise requiring payments to or from any such officer, director or employee or, to the Company’s knowledge, any corporation, partnership, trust or other entity in which any such officer,
director, or employee has a substantial interest or is an officer, director, trustee or partner. 
 (x) Internal Accounting Controls.
Except as disclosed in the SEC Reports or in Schedule 3.1(x), the Company and the Subsidiaries maintain a system of internal accounting controls sufficient to provide reasonable assurance that (i) transactions are executed in accordance
with management’s general or specific authorizations, (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with generally accepted accounting principles and to maintain asset
accountability, and (iii) access to assets is permitted only in accordance with management’s general or specific authorization. 
  

 -12- 

 (y) Sarbanes-Oxley Act. Except as disclosed in the SEC Reports, the Company is in compliance in
all material respects with applicable requirements of the Sarbanes-Oxley Act of 2002 and applicable rules and regulations promulgated by the SEC thereunder, except where such noncompliance would not have, individually or in the aggregate, a Material
Adverse Effect. 
 (z) Foreign Corrupt Practices. Neither the Company nor any of its Subsidiaries nor, to the knowledge of the
Company, any director, officer, agent, employee or other Person acting on behalf of the Company or any of its Subsidiaries pursuant to agreement with the Company has, in the course of its actions for, or on behalf of, the Company is in violation of
any provision of the U.S. Foreign Corrupt Practices Act of 1977, as amended. 
 (aa) Subsidiary Rights. Except as set forth in
Schedule 3.1(aa) or in the SEC Reports, the Company or one of its Subsidiaries has the unrestricted right to vote, and (subject to limitations imposed by applicable law or by the terms of agreements described in or filed as exhibits to the
SEC Reports) to receive dividends and distributions on, all capital securities of its Subsidiaries that are owned by the Company or such Subsidiary. 
 (bb) Tax Status. The Company and each of its Subsidiaries (ii) has paid all taxes and other governmental assessments and charges that are material in amount, shown or determined to be due on its foreign,
federal and state income tax returns, reports and declarations, except those being contested in good faith and (ii) has set aside on its books provision reasonably adequate for the payment of all taxes for periods subsequent to the periods to
which such returns, reports or declarations apply to the extent required under generally accepted accounting principles. There are no unpaid taxes in any material amount claimed to be due by the taxing authority of any jurisdiction. 
 (cc) Indebtedness. Except as disclosed in the SEC Reports, neither the Company nor any of its Subsidiaries is in violation of any term of or in
default under any contract, agreement or instrument relating to any Indebtedness, except where such violations and defaults would not result, individually or in the aggregate, in a Material Adverse Effect. For purposes of this Agreement:
(x) “Indebtedness” of any Person means, without duplication (A) all indebtedness for borrowed money, (B) all obligations issued, undertaken or assumed as the deferred purchase price of property or services (other than trade
payables entered into in the ordinary course of business), (C) all reimbursement or payment obligations with respect to letters of credit, surety bonds and other similar instruments, (D) all obligations evidenced by notes, bonds,
debentures or similar instruments, including obligations so evidenced incurred in connection with the acquisition of property, assets or businesses, (E) all indebtedness created or arising under any conditional sale or other title retention
agreement, or incurred as financing, in either case with respect to any property or assets acquired with the proceeds of such indebtedness (even though the rights and remedies of the seller or bank under such agreement in the event of default are
limited to repossession or sale of such property), (F) all monetary obligations under any leasing or similar arrangement which, in connection with generally accepted accounting principles, consistently applied for the periods covered thereby,
is classified as a capital lease, (G) all indebtedness referred to in clauses (A) through (F) above secured by (or for which the holder of such Indebtedness has an existing right, contingent or otherwise, to be secured by) any
mortgage, lien, pledge, charge, security interest or other encumbrance upon or in any property or assets (including accounts and contract rights) owned by any Person, even though the Person which owns such assets or property has not assumed or
become liable for the payment of 

  

 -13- 

 
such indebtedness, and (H) all Contingent Obligations in respect of indebtedness or obligations of others of the kinds referred to in clauses
(A) through (G) above; and (y) “Contingent Obligation” means, as to any Person, any direct or indirect liability, contingent or otherwise, of that Person with respect to any indebtedness, lease, dividend or other obligation
of another Person if the primary purpose or intent of the Person incurring such liability, or the primary effect thereof, is to provide assurance to the obligee of such liability that such liability will be paid or discharged, or that any agreements
relating thereto will be complied with, or that the holders of such liability will be protected (in whole or in part) against loss with respect thereto. 
 (dd) Labor Matters. The Company and its Material Subsidiaries are in compliance in all material respects with all federal, state, local and foreign laws and regulations respecting labor, employment and
employment practices and benefits, except where the failure to be in compliance would not, either individually or in the aggregate, have a Material Adverse Effect. 
 (ee) Environmental Laws. The Company and its Material Subsidiaries (i) are in compliance in all material respects with any and all Environmental Laws (as hereinafter defined), (ii) have received all
permits, licenses or other approvals required of them under applicable Environmental Laws to conduct their respective businesses and (iii) are in compliance in all material respects with all terms and conditions of any such permit, license or
approval except where, in each of the foregoing clauses (i), (ii) and (iii), the failure to so comply or so receive would, individually or in the aggregate, have a Material Adverse Effect. The term “Environmental Laws” means all
federal, state, local or foreign laws relating to pollution or protection of human health or the environment (including, without limitation, ambient air, surface water, groundwater, land surface or subsurface strata), including, without limitation,
laws relating to emissions, discharges, releases or threatened releases of chemicals, pollutants, contaminants, or toxic or hazardous substances or wastes (collectively, “Hazardous Materials”) into the environment, or otherwise relating to
the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials, as well as all authorizations, codes, decrees, demands or demand letters, injunctions, judgments, licenses, notices or notice
letters, orders, permits, plans or regulations issued, entered, promulgated or approved thereunder. 
 3.2 Representations and Warranties
of the Investors. Each Investor hereby, as to itself only and for no other Investor, represents and warrants to the Company as follows: 
 (a) Organization; Authority. Such Investor is an entity duly organized, validly existing and in good standing under the laws of the jurisdiction of its organization with the requisite corporate, partnership or other power and
authority to enter into and to consummate the transactions contemplated by the Transaction Documents and otherwise to carry out its obligations hereunder and thereunder. The purchase by such Investor of the Common Shares hereunder has been duly
authorized by all necessary action on the part of such Investor. This Agreement has been duly executed and delivered by such Investor and constitutes the valid and binding obligation of such Investor, enforceable against it in accordance with its
terms, except as may be limited by (i) applicable bankruptcy, insolvency, reorganization or other laws of general application relating to or affecting the enforcement of creditors rights generally, and (ii) the effect of rules of law
governing the availability of specific performance and other equitable remedies. 
  

 -14- 

 (b) No Public Sale or Distribution. Such Investor is acquiring the Common Shares in the ordinary
course of business for its own account and not with a view towards, or for resale in connection with, the public sale or distribution thereof, except pursuant to sales registered under the Securities Act or under an exemption from such registration
and in compliance with applicable federal and state securities laws, and such Investor does not have a present arrangement to effect any distribution of the Common Shares to or through any Person or entity; provided, however, that by
making the representations herein, such Investor does not agree to hold any of the Common Shares for any minimum or other specific term and reserves the right to dispose of the Common Shares at any time in accordance with or pursuant to a
registration statement or an exemption under the Securities Act. 
 (c) Investor Status. At the time such Investor was offered the
Common Shares, it was, and at the date hereof it is, an “accredited investor” pursuant to Sections (a)(1), (2), (3), (7) and (8) of Rule 501 under the Securities Act or a “qualified institutional buyer” as defined in
Rule 144A(a) under the Securities Act. Such Investor is not a registered broker dealer registered under Section 15(a) of the Exchange Act, or a member of the NASD, Inc. or an entity engaged in the business of being a broker dealer. Except as
otherwise disclosed in writing to the Company on Exhibit B-2 (attached hereto) on or prior to the date of this Agreement, such Investor is not affiliated with any broker dealer registered under Section 15(a) of the Exchange Act, or a
member of the NASD, Inc. or an entity engaged in the business of being a broker dealer. 
 (d) Experience of Such Investor. Such
Investor, either alone or together with its representatives has such knowledge, sophistication and experience in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment in the Common
Shares, and has so evaluated the merits and risks of such investment. Such Investor understands that it must bear the economic risk of this investment in the Common Shares indefinitely, and is able to bear such risk and is able to afford a complete
loss of such investment. 
 (e) Access to Information. Such Investor acknowledges that it has reviewed the Disclosure Materials and
has been afforded: (i) the opportunity to ask such questions as it has deemed necessary of, and to receive answers from, representatives of the Company concerning the terms and conditions of the offering of the Common Shares and the merits and
risks of investing in the Common Shares; (ii) access to information about the Company and the Subsidiaries and their respective financial condition, results of operations, business, properties, management and prospects sufficient to enable it
to evaluate its investment; and (iii) the opportunity to obtain such additional information that the Company possesses or can acquire without unreasonable effort or expense that is necessary to make an informed investment decision with respect
to the investment. Neither such inquiries nor any other investigation conducted by or on behalf of such Investor or its representatives or counsel shall modify, amend or affect such Investor’s right to rely on the truth, accuracy and
completeness of the Disclosure Materials and the Company’s representations and warranties contained in the Transaction Documents. Such Investor acknowledges receipt of copies of the SEC Reports. 
 (f) No Governmental Review. Such Investor understands that no United States federal or state agency or any other government or governmental agency
has passed on or made any recommendation or endorsement of the Common Shares or the fairness or suitability of the investment in the Common Shares nor have such authorities passed upon or endorsed the merits of the offering of the Common Shares.

  

 -15- 

 (g) No Conflicts. The execution, delivery and performance by such Investor of this Agreement and
the consummation by such Investor of the transactions contemplated hereby will not (i) result in a violation of the organizational documents of such Investor or (ii) conflict with, or constitute a default (or an event which with notice or
lapse of time or both would become a default) under, or give to others any rights of termination, amendment, acceleration or cancellation of, any agreement, indenture or instrument to which such Investor is a party, or (iii) result in a
violation of any law, rule, regulation, order, judgment or decree (including federal and state securities laws) applicable to such Investor, except in the case of clauses (ii) and (iii) above, for such that are not material and do not
otherwise affect the ability of such Investor to consummate the transactions contemplated hereby. 
 (h) Transactions in Securities.
No Investor, directly or indirectly, and no Person acting on behalf of or pursuant to any understanding with any Investor, has (i) engaged in any purchase or sale (including, without limitation, any Short Sales involving any of the
Company’s securities), (ii) contracted to or granted any option to purchase or sell (including, without limitation, any Short Sales involving any of the Company’s securities), (iii) established, liquidated, increased or decreased
a “put equivalent position” or a “call equivalent position” within the meaning of Rule 16a-1 under the Exchange Act, or (iv) otherwise disposed of securities of the Company (including, without limitation, any Short Sales
involving any of the Company’s securities), since the time that such Investor was first contacted by the Company, the Agent or any other Person regarding this investment in the Company, in each case, other than the purchase of the Common Shares
pursuant to this Agreement. The transactions described in clauses (i) through (iv) of the preceding sentence are referred to herein as “Specified Transactions.” Such Investor covenants that neither it nor any Person acting
on its behalf or pursuant to any understanding with such Investor will engage, directly or indirectly, in any Specified Transactions in the securities of the Company (including Short Sales) prior to the time the transactions contemplated by this
Agreement are publicly disclosed. “Short Sales” include, without limitation, all “short sales” as defined in Rule 200 promulgated under Regulation SHO under the Exchange Act and all types of direct and indirect stock
pledges, forward sale contracts, options, puts, calls, short sales, swaps, derivatives and similar arrangements (including on a total return basis), and sales and other transactions through non-U.S. broker-dealers or foreign regulated brokers.
Notwithstanding the foregoing, with respect to LB I Group Inc., this Section 3.2(h) shall apply to the Global Trading Strategies group, as currently configured, of Lehman Brothers Holdings Inc., and shall not apply to any other person,
affiliate, subsidiary, business unit, area, group or division of Lehman Brothers Holdings Inc. who has not been notified of the transactions contemplated by this Agreement. 
 (i) Restricted Securities. The Investors understand that the Common Shares are characterized as “restricted securities” under the U.S.
federal securities laws inasmuch as they are being acquired from the Company in a transaction not involving a public offering and that under such laws and applicable regulations such securities may be resold without registration under the Securities
Act only in certain limited circumstances. 
  

 -16- 

 (j) Legends. It is understood that, except as provided in Section 4.1(b) of this
Agreement, certificates evidencing such Common Shares may bear the legend set forth in Section 4.1(b). 
 (k) No Legal, Tax or
Investment Advice. Such Investor understands that nothing in this Agreement or any other materials presented by or on behalf of the Company to the Investor in connection with the purchase of the Common Shares constitutes legal, tax or investment
advice. Such Investor has consulted such legal, tax and investment advisors as it, in its sole discretion, has deemed necessary or appropriate in connection with its purchase of the Common Shares. Such Investor understands that the Agent has acted
solely as the agent of the Company in this placement of the Common Shares, and that the Agent makes no representation or warranty with regard to the merits of this transaction or as to the accuracy of any information such Investor may have received
in connection therewith. Such Investor acknowledges that he has not relied on any information or advice furnished by or on behalf of the Agent. 
 ARTICLE IV 
 OTHER AGREEMENTS OF THE PARTIES 
 4.1 Transfer Restrictions. 
 (a) The Investors covenant that the Common Shares will only be disposed
of pursuant to an effective registration statement under, and in compliance with the requirements of, the Securities Act or pursuant to an available exemption from the registration requirements of the Securities Act, and in compliance with any
applicable state securities laws. In connection with any transfer of Common Shares other than pursuant to an effective registration statement or to the Company, the Company may require the transferor to provide to the Company an opinion of counsel
selected by the transferor, the form and substance of which opinion shall be reasonably satisfactory to the Company, to the effect that such transfer does not require registration under the Securities Act. Notwithstanding the foregoing, the Company
hereby consents to and agrees to register on the books of the Company and with its Transfer Agent, without any such legal opinion, except to the extent that the Transfer Agent requests such legal opinion, any transfer of Common Shares by an Investor
to an Affiliate of such Investor, provided that the transferee certifies to the Company that it is an “accredited investor” as defined in Rule 501(a) under the Securities Act and provided that such Affiliate does not request any removal of
any existing legends on any certificate evidencing the Common Shares. 
 (b) The Investors agree to the imprinting, so long as is required by
this Section 4.1(b), of the following legend on any certificate evidencing any of the Common Shares: 
 THESE SECURITIES HAVE NOT
BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY
APPLICABLE STATE SECURITIES LAWS AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, 

  

 -17- 

 
OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN COMPLIANCE WITH APPLICABLE STATE SECURITIES LAWS OR BLUE SKY
LAWS. NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN OR FINANCING ARRANGEMENT SECURED BY THE SECURITIES. 
 Certificates evidencing Common Shares shall not be required to contain such legend or any other legend (i) while a registration statement (including the Registration Statement) covering the resale of the Common
Shares is effective under the Securities Act, (ii) following any sale of such Common Shares pursuant to Rule 144 if the holder provides the Company with a legal opinion (and the documents upon which the legal opinion is based) reasonably
acceptable to the Company to the effect that the Common Shares can be sold under Rule 144, (iii) if the holder provides the Company with a legal opinion (and the documents upon which the legal opinion is based) reasonably acceptable to the
Company to the effect that the Common Shares are eligible for sale under Rule 144(k), or (iv) if the holder provides the Company with a legal opinion (and the documents upon which the legal opinion is based) reasonably acceptable to the Company
to the effect that the legend is not required under applicable requirements of the Securities Act (including controlling judicial interpretations and pronouncements issued by the Staff of the SEC). The Company shall cause its counsel to issue the
formal written confirmation included in the Transfer Agent Instructions to the Transfer Agent on the Effective Date. Following the Effective Date or at such earlier time as a legend is no longer required for certain Common Shares, the Company will
no later than three Trading Days following the delivery by an Investor to the Company or the Transfer Agent of (i) a legended certificate representing such Common Shares, and (ii) an opinion of counsel to the extent required by
Section 4.1(a), deliver or cause to be delivered to such Investor a certificate representing such Common Shares that is free from all restrictive and other legends. The Company shall issue an instruction to the Transfer Agent as set
forth in Exhibit E hereto with respect to requests by Holders to issue such Common Shares in accordance with the foregoing sentence via The Depository Trust Company’s Deposit/Withdrawal at Custodian, or DWAC system. The Company may not
make any notation on its records or give instructions to the Transfer Agent that enlarge the restrictions on transfer set forth in this Section. 
 If within
three Trading Days after the Company’s receipt of a legended certificate and the other documents as specified in Clauses (i) and (ii) of the paragraph immediately above, the Company shall fail to issue and deliver to such Investor a
certificate representing such Securities that is free from all restrictive and other legends, and if on or after such third Trading Day the Investor purchases (in an open market transaction or otherwise) shares of Common Stock to deliver in
satisfaction of a sale by the Investor of shares of Common Stock that the Investor anticipated receiving from the Company without any restrictive legend (the “Covering Shares”), then the Company shall, within three Trading Days after the
Investor’s request, pay cash to the Investor in an amount equal to the excess (if any) of the Investor’s total purchase price (including brokerage commissions, if any, up to $100 in the aggregate for any Investor) for the Covering Shares,
over the product of (A) the number of Covering Shares, times (B) the closing bid price on the date of delivery of such certificate and the other documents as specified in Clauses (i) and (ii) of the paragraph immediately above.
The Company shall pay all fees of the Transfer Agent in connection with this Section 4.1(b). 
  

 -18- 

 (c) The Company will not object to and shall permit (except as prohibited by law) an Investor to pledge
or grant a security interest in some or all of the Common Shares in connection with a bona fide margin agreement or other bona fide loan or financing arrangement secured by the Common Shares, and if required under the terms of such bona fide
agreement, loan or arrangement, the Company will not object to and shall permit (except as prohibited by law) such Investor to transfer pledged or secured Common Shares to the pledgee or secured parties. Except as required by law, such a pledge or
transfer would not be subject to approval of the Company, no legal opinion of the pledgee, secured party or pledgor shall be required in connection therewith, and no notice shall be required of such pledge. Each Investor acknowledges that the
Company shall not be responsible for any pledges relating to, or the grant of any security interest in, any of the Common Shares or for any agreement, understanding or arrangement between any Investor and its pledgee or secured party. At the
appropriate Investor’s expense, the Company will execute and deliver such reasonable documentation as a pledgee or secured party of Common Shares may reasonably request in connection with a pledge or transfer of the Common Shares, including the
preparation and filing of any required prospectus supplement under Rule 424(b)(3) of the Securities Act or other applicable provision of the Securities Act to appropriately amend the list of Selling Stockholders thereunder. Notwithstanding the
foregoing, each Investor agrees that no such pledge, grant of security interest or transfer shall be made in violation of the Securities Act. Neither the Company’s indemnification obligations pursuant to Section 6.4 or the
Company’s contribution obligations pursuant to Section 6.4(d) shall extend to any Proceeding or Losses arising out of or related to this Section 4.1(c). 
 4.2 Furnishing of Information. Until the date that any Investor owning Common Shares may sell all of them under Rule 144(k) of the Securities Act
(or any successor provision), the Company covenants to use its reasonable Best Efforts to timely file (or obtain extensions in respect thereof and file within the applicable grace period) all reports required to be filed by the Company after the
date hereof pursuant to the Exchange Act. Until the date that any Investor owning Common Shares may sell all of them under Rule 144(k) of the Securities Act (or any successor provision), the Company further covenants that it will take such further
action as any holder of Common Shares may reasonably request to make available the information specified in paragraph (c) of Rule 144. 
 4.3 Integration. The Company shall not, and shall use its commercially reasonably efforts to ensure that no Affiliate of the Company shall, sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any
security (as defined in Section 2 of the Securities Act) that would be integrated with the offer or sale of the Common Shares in a manner that would require the registration under the Securities Act of the sale of the Common Shares to the
Investors or that would be integrated with the offer or sale of the Common Shares for purposes of the rules and regulations of any Trading Market. 
 4.4 Securities Laws Disclosure; Publicity. The Company shall, on or before 9:30 a.m., New York time, on the first Trading Day following execution of this Agreement, issue a press release reasonably acceptable to the Investor
acquiring the largest number of Common Shares disclosing all material terms of the transactions contemplated hereby. On or prior to the Closing Date, the Company shall file a Current Report on Form 8-K with the SEC (the “8-K
Filing”) describing the 

  

 -19- 

 
terms of the transactions contemplated by the Transaction Documents and including as an exhibit to such Current Report on Form 8-K this Agreement (including
the schedules and the names, and addresses of the Investors and the amount(s) of Common Shares respectively purchased), in the form required by the Exchange Act. Thereafter, the Company shall timely file any filings and notices required by the SEC
or applicable law with respect to the transactions contemplated hereby. Except as herein provided, and except for disclosure in the Registration Statement, the Company shall not publicly disclose the name of any Investor, or include the name of any
Investor in any press release without the prior written consent of such Investor, unless otherwise required by law or Trading Market regulations. The Company shall not, and shall cause each of its Subsidiaries not to, and shall instruct its and each
of their respective officers, directors, employees and agents not to, provide any Investor with any material nonpublic information regarding the Company or any of its Subsidiaries from and after the issuance of the above referenced press release
without the express written consent of such Investor and the Company. No Investor shall issue any press release or otherwise make any public statement, filing or other communication with respect to the transactions contemplated by the Transaction
Documents without the prior consent of the Company, except if such disclosure is required by law, in which case the Investor shall promptly provide the Company with prior notice of such public statement, filing or other communication in a manner
which affords, when reasonably available, an opportunity for the Company to review and comment on the proposed disclosure. 
 4.5 Use of
Proceeds. The Company intends to use the net proceeds from the sale of the Common Shares for working capital and general corporate purposes, including, but not limited to acquiring or investing in technologies, products, services or other
businesses, although the Company has no material commitments with respect to these types of transactions. Pending these uses, the Company intends to invest the net proceeds from this offering in short-term, interest-bearing, investment-grade
securities, or as otherwise pursuant to the Company’s customary investment policies. 
 ARTICLE V 
 CONDITIONS 
 5.1 Conditions Precedent to
the Obligations of the Investors. The obligation of each Investor to acquire Common Shares at the Closing is subject to the satisfaction or waiver by such Investor, at or before the Closing, of each of the following conditions: 
 (a) Representations and Warranties. The representations and warranties of the Company contained herein shall be true and correct in all material
respects as of the date when made and as of the Closing as though made on and as of such date; and 
 (b) Performance. The Company and
each other Investor shall have performed, satisfied and complied in all material respects with all covenants, agreements and conditions required by the Transaction Documents to be performed, satisfied or complied with by it at or prior to the
Closing. 
 5.2 Conditions Precedent to the Obligations of the Company. The obligation of the Company to sell the Common Shares at the
Closing is subject to the satisfaction or waiver by the Company, at or before the Closing, of each of the following conditions: 
 (a)
Representations and Warranties. The representations and warranties of the Investors contained herein shall be true and correct in all material respects as of the date when made and as of the Closing Date as though made on and as of such date;
and 
  

 -20- 

 (b) Performance. The Investors shall have performed, satisfied and complied in all material
respects with all covenants, agreements and conditions required by the Transaction Documents to be performed, satisfied or complied with by the Investors at or prior to the Closing. 
 ARTICLE VI 
 REGISTRATION RIGHTS 
 6.1 Registration Statement. 
 (a) As
promptly as possible, and in any event on or prior to the Filing Date, the Company shall prepare and file with the SEC a Registration Statement on Form S-1, or other appropriate form on which the Company is then eligible to file a Registration
Statement in accordance with the Securities Act and the Exchange Act, covering the resale of all Registrable Securities for an offering to be made on a continuous basis pursuant to Rule 415. The Registration Statement shall contain (except if
otherwise directed by the Investors or requested by the SEC) the “Plan of Distribution” in substantially the form attached hereto as Exhibit D. 
 (b) The Company shall use its commercially reasonable efforts to cause the Registration Statement to be declared effective by the SEC as promptly as possible after the filing thereof, but in any event prior to the
Required Effectiveness Date, and shall use its commercially reasonable efforts to keep the Registration Statement continuously effective under the Securities Act until the earlier of the date that all Common Shares covered by such Registration
Statement have been sold or can be sold publicly under Rule 144(k) but in no event for a period of more than two years from the Closing Date (the “Effectiveness Period”); provided that, upon notification by the SEC that a
Registration Statement will not be reviewed or is no longer subject to further review and comments, the Company, within five (5) Trading Days after receipt of such notice, shall request acceleration of such Registration Statement and request
that such Registration Statement becomes effective after 4:00 p.m. New York City time on the Effective Date. 
 (c) The Company shall notify
the Investors in writing promptly (and in any event within two Trading Days) after receiving notification from the SEC that the Registration Statement has been declared effective. 
 (d) Should an Event (as defined below) occur, then upon the occurrence of such Event and on every monthly anniversary thereof until the applicable Event
is cured, the Company shall pay to each Investor who provides to the Company reasonable written evidence of its ownership of the Common Shares at the time of each such Event (including the number of Common Shares held by such Investor as of each
such date) an amount in cash, as liquidated damages and not as a penalty, equal to three-quarters of one percent (0.75%) of (i) the number of Common Shares held by such Investor as of the date of such Event, multiplied by (ii) the purchase
price paid by such Investor for such Common Shares then held; provided, however, that the total amount of payments pursuant to this Section 6.1(d) shall not exceed, when aggregated with all such payments paid to all Investors, ten
percent (10%) of the aggregate purchase price. The payments to which an Investor 

  

 -21- 

 
shall be entitled pursuant to this Section 6.1(d) are referred to herein as “Event Payments.” Any Event Payments payable
pursuant to the terms hereof shall apply on a pro rated basis for any portion of a month prior to the cure of an Event. In the event the Company fails to make Event Payments in a timely manner, such Event Payments shall bear interest at the rate of
one percent (1.0%) per month (prorated for partial months) commencing thirty (30) days after the Investor provided such reasonable evidence of ownership hereunder until paid in full. All pro rated calculations made pursuant to this
paragraph shall be based upon the actual number of days in such pro rated month. 
 For such purposes, each of the following shall constitute an
“Event”: 
 (i) the Registration Statement is not filed on or prior to the Filing Date; 
 (ii) the Registration Statement is not declared effective on or prior to the Required Effectiveness Date; 
 (iii) except as provided for in Section 6.1(e) (the “Excluded Events”), after the Effective Date but prior to the end of
the Effectiveness Period, an Investor is not permitted to sell Registrable Securities under the Registration Statement (or a subsequent Registration Statement filed in replacement thereof) for any reason (other than the fault of such Investor) for
fifteen (15) or more consecutive Trading Days during the Effectiveness Period; or 
 (iv) with respect to an Investor, the Company
fails for any reason to deliver a certificate evidencing any Common Shares to such Investor within five Trading Days after delivery of such certificate is required pursuant to any Transaction Document, other than as a result of the fault of an
Investor. 
 (e) Notwithstanding anything in this Agreement to the contrary, after the 45th Trading Day following the Effective Date, the Company may, by written notice to the Investors, suspend sales under a Registration Statement after the
Effective Date thereof and/or require that the Investors immediately cease the sale of shares of Common Stock pursuant thereto and/or defer the filing of any subsequent Registration Statement if the Company is engaged in a material merger,
acquisition or sale and the Board of Directors determines in good faith, by appropriate resolutions, that, as a result of such activity, (A) it would be materially detrimental to the Company (other than as relating solely to the price of the
Common Stock) to maintain a Registration Statement at such time or (B) it is in the best interests of the Company to suspend sales under such registration at such time. Upon receipt of such notice, each Investor shall immediately discontinue
any sales of Registrable Securities pursuant to such registration until such Investor is advised in writing by the Company that the current Prospectus or amended Prospectus, as applicable, may be used. In no event, however, shall this right be
exercised to suspend sales beyond the period during which (in the good faith determination of the Company’s Board of Directors) the failure to require such suspension would be materially detrimental to the Company. The Company’s rights
under this Section 6(e) may be exercised for a period of no more than 20 Trading Days at a time and not more than three times in any twelve-month period, without such suspension being considered as part of an Event Payment determination.
Immediately after the end of any suspension period under this Section 6(e), the Company shall take all necessary actions (including filing any required supplemental prospectus) to restore the effectiveness of the applicable Registration
Statement and the ability of the Investors to publicly resell their Registrable Securities pursuant to such effective Registration Statement. 
  

 -22- 

 (f) The Company shall not, from the date hereof until the Effective Date of the Registration Statement,
prepare and file with the SEC a registration statement relating to an offering for its own account or the account of others under the Securities Act of any of its equity securities, other than any reasonably necessary or advisable amendment to a
registration statement that was filed with SEC prior to the Closing Date and other than any registration statement or post-effective amendment to a registration statement (or supplement thereto) relating to the Company’s employee benefit plans
registered on Form S-8. 
 (g) Notwithstanding anything in the Transaction Documents to the contrary, it shall be a condition precedent to
the obligations of the Company to complete the registration pursuant to this Agreement with respect to the Registrable Securities of any particular Investor or to make any Event Payments set forth in Section 6.1(c) to such Investor that
such Investor timely furnish to the Company the information specified in Exhibits B-1, B-2, B-3 and B-4 hereto and such other information regarding itself, the Registrable Securities and other shares of Common Stock held
by it and the intended method of disposition of the Registrable Securities held by it (if different from the Plan of Distribution set forth on Exhibit D hereto) as shall be reasonably required to effect the registration of such Registrable
Securities and each Investor shall complete and timely execute such documents in connection with such registration as the Company may reasonably request. 
 6.2 Registration Procedures. In connection with the Company’s registration obligations under Section 6.1(a) and Section 6.1(b), the Company shall: 
 (a) Not less than three Trading Days prior to the filing of a Registration Statement or any related Prospectus or any amendment or supplement thereto,
furnish via email to those Investors who have supplied the Company with email addresses on the signature pages hereto copies of all such documents proposed to be filed, which documents (other than any document that is incorporated or deemed to be
incorporated by reference therein) will be subject to the review of such Investors. The Company shall reflect in each such document when so filed with the SEC such comments regarding the Investors as the Investors may reasonably and promptly propose
no later than two days after the Investors have been so furnished with copies of such documents as aforesaid. 
 (b) (i) Subject to
Section 6.1(e), prepare and file with the SEC such amendments, including post-effective amendments, to each Registration Statement and the Prospectus used in connection therewith as may be necessary to keep the Registration Statement
continuously effective, as to the applicable Registrable Securities for the Effectiveness Period and prepare and file with the SEC such additional Registration Statements in order to register for resale under the Securities Act all of the
Registrable Securities; (ii) cause the related Prospectus to be amended or supplemented by any required Prospectus supplement, and as so supplemented or amended to be filed pursuant to Rule 424; (iii) respond as promptly as reasonably
possible, and in any event within twelve (12) Trading Days (except to the extent that the Company reasonably requires additional time to respond to comments), to any comments received from the SEC with respect to the Registration Statement or
any amendment thereto; and (iv) comply in all material respects with the provisions of the Securities Act and the Exchange Act with respect to the disposition of all Registrable Securities covered by the Registration Statement during the
applicable period in accordance with the intended methods of disposition by the Investors thereof set forth in the Registration Statement as so amended or in such Prospectus as so supplemented. 
  

 -23- 

 (c) Notify those Investors who have supplied the Company with e-mail addresses on the signature pages
hereto as promptly as reasonably possible, and (if requested by the Investors confirm such notice in writing no later than two Trading Days thereafter, of any of the following events: (i) the SEC notifies the Company whether there will be a
“review” of any Registration Statement; (ii) the SEC comments in writing on any Registration Statement; (iii) any Registration Statement or any post-effective amendment is declared effective; (iv) the SEC or any other
Federal or state governmental authority requests any amendment or supplement to any Registration Statement or Prospectus or requests additional information related thereto; (v) the SEC issues any stop order suspending the effectiveness of any
Registration Statement or initiates any Proceedings for that purpose; (vi) the Company receives notice of any suspension of the qualification or exemption from qualification of any Registrable Securities for sale in any jurisdiction, or
receives written notice of the initiation or threat of any Proceeding for such purpose; or (vii) the financial statements included in any Registration Statement become ineligible for inclusion therein or any Registration Statement or Prospectus
or other document contains any untrue statement of a material fact or omits to state any material fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances under which they were made, not
misleading. 
 (d) Use its reasonable Best Efforts to avoid the issuance of or, if issued, obtain the withdrawal of (i) any order
suspending the effectiveness of any Registration Statement, or (ii) any suspension of the qualification (or exemption from qualification) of any of the Registrable Securities for sale in any jurisdiction, as soon as practicable. 
 (e) If requested by an Investor, provide such Investor, without charge, at least one conformed copy of each Registration Statement and each amendment
thereto, including financial statements and schedules, and all exhibits to the extent requested by such Person (including those previously furnished or incorporated by reference) promptly after the filing of such documents with the SEC. 

(f) Promptly deliver to each Investor, without charge, as many copies of the Prospectus or Prospectuses (including each form of prospectus) and each
amendment or supplement thereto as such Persons may reasonably request. The Company hereby consents to the use of such Prospectus and each amendment or supplement thereto by each of the selling Investors in connection with the offering and sale of
the Registrable Securities covered by such Prospectus and any amendment or supplement thereto (in the manner described in the Prospectus) to the extent permitted by federal and state securities laws and regulations. 
 (g) (i) In the time and manner required by each Trading Market, prepare and file with such Trading Market an additional shares listing application
covering all of the Registrable Securities; (ii) use commercially reasonable efforts to cause such Common Shares to be approved for listing on each Trading Market as soon as reasonably possible thereafter; and (iii) except as a result of
the Excluded Events, during the Effectiveness Period, use commercially reasonable efforts to maintain the listing of such Common Shares on each such Trading Market or another Eligible Market. 
 (h) Prior to any public offering of Registrable Securities, use its reasonable Best Efforts to register or qualify or cooperate with the selling
Investors in connection with the registration or qualification (or exemption from such registration or qualification) of such 

  

 -24- 

 
Registrable Securities for offer and sale under the securities or blue sky laws of such jurisdictions within the United States as any Investor requests in
writing, to keep each such registration or qualification (or exemption therefrom) effective for so long as required, but not to exceed the duration of the Effectiveness Period, and to do any and all other acts or things reasonably necessary or
advisable to enable the disposition in such jurisdictions in the United States of the Registrable Securities covered by a Registration Statement; provided, however, that the Company shall not be obligated to file any general consent to
service of process or to qualify as a foreign corporation or as a dealer in securities in any jurisdiction in which it is not so qualified or to subject itself to taxation in respect of doing business in any jurisdiction in which it is not otherwise
so subject. 
 (i) Cooperate with the Investors to facilitate the timely preparation and delivery of certificates representing Registrable
Securities to be delivered to a transferee pursuant to a Registration Statement, which certificates shall be free, to the extent permitted by this Agreement and under law, of all restrictive legends, and to enable such Registrable Securities to be
in such denominations and registered in such names as any such Investors may reasonably request. 
 (j) Upon the occurrence of any event
described in Section 6.2(c)(vii), as promptly as reasonably possible, prepare a supplement or amendment, including a post-effective amendment, to the Registration Statement or a supplement to the related Prospectus or any document
incorporated or deemed to be incorporated therein by reference, and file any other required document so that, as thereafter delivered, neither the Registration Statement nor such Prospectus will contain an untrue statement of a material fact or omit
to state a material fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading. 
 (k) Cooperate with any reasonable due diligence investigation undertaken by the Investors in connection with the sale of Registrable Securities,
including, without limitation, by making available documents and information; provided that the Company will not deliver or make available to any Investor material, nonpublic information unless such Investor requests in advance in writing to receive
material, nonpublic information and agrees to keep such information confidential. 
 (l) Use commercially reasonable efforts to comply with
all rules and regulations of the SEC applicable to the registration of the Common Shares. 
 (m) Comply with all applicable rules and
regulations of the SEC under the Securities Act and the Exchange Act, including, without limitation, Rule 172 under the Securities Act, file any final Prospectus, including any supplement or amendment thereof, with the SEC pursuant to Rule 424 under
the Securities Act, promptly inform the Investors in writing if, at any time during the Effectiveness Period, the Company does not satisfy the conditions specified in Rule 172 and, as a result thereof, the Investors are required to make available a
Prospectus in connection with any disposition of Registrable Securities and take such other actions as may be reasonably necessary to facilitate the registration of the Registrable Securities hereunder. 
 6.3 Registration Expenses. The Company shall pay all fees and expenses incident to the performance of or compliance with Article VI of this
Agreement by the Company, including without limitation (a) all registration and filing fees and expenses, including without limitation those related to filings with the SEC, any Trading Market and in connection with applicable state securities
or 

  

 -25- 

 
blue sky laws, (b) printing expenses (including without limitation expenses of printing certificates for Registrable Securities), (c) messenger,
telephone and delivery expenses, (d) fees and disbursements of counsel for the Company, (e) fees and expenses of all other Persons retained by the Company in connection with the consummation of the transactions contemplated by this
Agreement, and (f) all listing fees to be paid by the Company to the Trading Market. The Investors shall be responsible for paying the underwriters’ commission or brokerage fees and taxes of any kind (including, without limitation,
transfer taxes) applicable to any disposition, sale or transfer of Registrable Securities. 
 6.4 Indemnification 
 (a) Indemnification by the Company. The Company shall, notwithstanding any termination of this Agreement, indemnify and hold harmless each
Investor, the officers, directors, partners, members, agents and employees of each of them, each Person who controls any such Investor (within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act) and the
officers, directors, partners, members, agents and employees of each such controlling Person, to the fullest extent permitted by applicable law, from and against any and all Losses, as incurred, arising out of or relating to (i) any breach of
any representation or warranty made by the Company in this Agreement, (ii) any failure of the Company to comply with any covenant or agreement of the Company contained in this Agreement, or (iii) any untrue or alleged untrue statement of a
material fact contained in the Registration Statement, any Prospectus or any form of Company prospectus or in any amendment or supplement thereto or in any Company preliminary prospectus, or arising out of or relating to any omission or alleged
omission of a material fact required to be stated therein or necessary to make the statements therein (in the case of any Prospectus or form of prospectus or supplement thereto, in the light of the circumstances under which they were made) not
misleading, except to the extent, but only to the extent, that (A) such untrue statements, alleged untrue statements, omissions or alleged omissions are made in reliance upon and in strict conformity with information regarding such Investor
furnished in writing to the Company by such Investor expressly for use therein, or (B) with respect to any prospectus, if the untrue statement or omission of material fact contained in such prospectus was corrected on a timely basis in the
prospectus, as then amended or supplemented, if such corrected prospectus was timely made available by the Company to the Investor, and the Investor seeking indemnity hereunder was advised in writing not to use the incorrect prospectus prior to the
use giving rise to Losses; but, with respect to clauses (i) and (ii) above, only to the extent such Losses do not arise out of or relate to (I) any breach of a representation or warranty made by such Investor in this Agreement or (II)
any failure to comply by such Investor with any covenant or agreement of such Investor contained in this Agreement. 
 (b) Indemnification
by Investors. Each Investor shall, severally and not jointly, indemnify and hold harmless the Company, its directors, officers, agents and employees, each Person who controls the Company (within the meaning of Section 15 of the Securities
Act and Section 20 of the Exchange Act), and the directors, officers, agents or employees of such controlling Persons, to the fullest extent permitted by applicable law, from and against all Losses, as incurred, arising out of or relating to
(i) any breach of any representation or warranty made by such Investor in this Agreement, (ii) any failure of the Investor to comply with any covenant, agreement or obligation of such Investor contained in this Agreement, or (iii) any
untrue statement of a material fact contained in the Registration Statement, any Prospectus, or any form of prospectus, or in any amendment or supplement thereto, or arising out of or relating to any omission of a material fact 

  

 -26- 

 
required to be stated therein or necessary to make the statements therein (in the case of any Prospectus or form of prospectus or supplement thereto, in the
light of the circumstances under which they were made) not misleading, but only to the extent that (A) such untrue statements or omissions are made in reliance upon and in strict conformity with information regarding such Investor furnished to
the Company by such Investor in writing expressly for use therein, (B) such information relates to such Investor or such Investor’s proposed method of distribution of Registrable Securities and was reviewed and expressly approved by such
Investor expressly for use in the Registration Statement (it being understood that the information provided by the Investor to the Company in Exhibits B-1, B-2, B-3 and B-4 and the Plan of Distribution set forth on
Exhibit D, and other information provided by the Investor to the Company in or pursuant to the Transaction Documents constitutes information reviewed and expressly approved by such Investor in writing expressly for use in the Registration
Statement), or (C) if the Company has provided a notice under Section 6.1(e) or in the case of an occurrence of an event of the type specified in Section 6.2(c)(iv) (in the case of a request for an amendment), (v),
(vi) or (vii), the use by such Investor of the Prospectus after the Company has notified such Investor in writing pursuant to Section 6.1(e) or 6.2(c) and prior to the receipt by such Investor pursuant to
Section 6.1(e) or 6.2(c) that the Prospectus, as then amended or supplemented, may be used; but, with respect to clauses (i) and (ii) above, only to the extent such Losses do not arise out of or relate to (I) any
breach of any representation or warranty made by the Company in this Agreement or (II) any failure of the Company to comply with any covenant or agreement of the Company contained in this Agreement. In no event shall the liability of any selling
Investor hereunder be greater in amount than the dollar amount of the net proceeds received by such Investor upon the sale of the Registrable Securities giving rise to such indemnification obligation. 
 (c) Conduct of Indemnification Proceedings. If any Proceeding shall be brought or asserted against any Person entitled to indemnity hereunder (an
“Indemnified Party”), such Indemnified Party shall promptly notify the Person from whom indemnity is sought (the “Indemnifying Party”) in writing, and the Indemnifying Party shall assume the defense thereof,
including the employment of counsel reasonably satisfactory to the Indemnified Party and the payment of all fees and expenses incurred in connection with defense thereof; provided, that the failure of any Indemnified Party to give such notice shall
not relieve the Indemnifying Party of its obligations or liabilities pursuant to this Agreement, except (and only) to the extent that it shall be finally determined by a court of competent jurisdiction (which determination is not subject to appeal
or further review) that such failure shall have proximately and materially adversely prejudiced the Indemnifying Party. 
 An Indemnified
Party shall have the right to employ separate counsel in any such Proceeding and to participate in the defense thereof, but the fees and expenses of such counsel shall be at the expense of such Indemnified Party or Parties unless: (i) the
Indemnifying Party has agreed in writing to pay such fees and expenses; or (ii) the Indemnifying Party shall have failed promptly to assume the defense of such Proceeding and to employ counsel reasonably satisfactory to such Indemnified Party
in any such Proceeding; or (iii) the named parties to any such Proceeding (including any impleaded parties) include both such Indemnified Party and the Indemnifying Party, and such Indemnified Party shall have been advised by counsel that a
conflict of interest is likely to exist if the same counsel were to represent such Indemnified Party and the Indemnifying Party (in which case, if such Indemnified Party notifies the Indemnifying Party in writing that it elects to employ separate
counsel at the expense of the Indemnifying Party, the Indemnifying Party shall not 

  

 -27- 

 
have the right to assume the defense thereof and the reasonable fees and expenses of separate counsel shall be at the expense of the Indemnifying Party). It
being understood, however, that the Indemnifying Party shall not, in connection with any one such Proceeding (including separate Proceedings that have been or will be consolidated before a single judge) be liable for the fees and expenses of more
than one separate firm of attorneys at any time for all Indemnified Parties, which firm shall be appointed by a majority of the Indemnified Parties. The Indemnifying Party shall not be liable for any settlement of any such Proceeding effected
without its written consent, which consent shall not be unreasonably withheld. No Indemnifying Party shall, without the prior written consent of the Indemnified Party, effect any settlement of any pending Proceeding in respect of which any
Indemnified Party is a party, unless such settlement includes an unconditional release of such Indemnified Party from all liability on claims that are the subject matter of such Proceeding. 
 All reasonable fees and expenses of the Indemnified Party (including reasonable fees and expenses to the extent incurred in connection with investigating
or preparing to defend such Proceeding in a manner not inconsistent with this Section) shall be paid to the Indemnified Party, as incurred, within 20 Trading Days of written notice thereof to the Indemnifying Party (regardless of whether it is
ultimately determined that an Indemnified Party is not entitled to indemnification hereunder; provided, that the Indemnifying Party may require such Indemnified Party to undertake to reimburse all such fees and expenses to the extent it is finally
judicially determined that such Indemnified Party is not entitled to indemnification hereunder). 
 (d) Contribution. If a claim for
indemnification under Section 6.4(a) or (b) is unavailable to an Indemnified Party (by reason of public policy or otherwise, but other than by reason of the specified exclusions to indemnification under
Section 6.4(a) or (b)), then each Indemnifying Party, in lieu of indemnifying such Indemnified Party, shall contribute to the amount paid or payable by such Indemnified Party as a result of such Losses, in such proportion as is
appropriate to reflect the relative fault of the Indemnifying Party and Indemnified Party in connection with the actions, statements or omissions that resulted in such Losses as well as any other relevant equitable considerations. The relative fault
of such Indemnifying Party and Indemnified Party shall be determined by reference to, among other things, whether any action in question, including any untrue or alleged untrue statement of a material fact or omission or alleged omission of a
material fact, has been taken or made by, or relates to information supplied by, such Indemnifying Party or Indemnified Party, and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such action,
statement or omission. The amount paid or payable by a party as a result of any Losses shall be deemed to include, subject to the limitations set forth in Section 6.4(c), any reasonable attorneys’ or other reasonable fees or
expenses incurred by such party in connection with any Proceeding to the extent such party would have been indemnified for such fees or expenses if the indemnification provided for in this Section was available to such party in accordance with its
terms. 
 The parties hereto agree that it would not be just and equitable if contribution pursuant to this Section 6.4(d) were
determined by pro rata allocation or by any other method of allocation that does not take into account the equitable considerations referred to in the immediately preceding paragraph. Notwithstanding the provisions of this
Section 6.4(d), no Investor shall be required to contribute, in the aggregate, any amount in excess of the amount by which the proceeds actually received by such Investor from the sale of the Registrable Securities subject to the
Proceeding exceeds the amount of any damages that such Investor has otherwise been required to pay by reason 

  

 -28- 

 
of such untrue or alleged untrue statement or omission or alleged omission. No Person guilty of fraudulent misrepresentation (within the meaning of
Section 11(f) of the Securities Act) shall be entitled to contribution from any Person who was not guilty of such fraudulent misrepresentation. 
 The indemnity and contribution agreements contained in this Section are in addition to any liability that the Indemnifying Parties may have to the Indemnified Parties. 
 6.5 Dispositions. Each Investor agrees that it will comply with the prospectus delivery requirements of the Securities Act as applicable to it in
connection with sales of Registrable Securities pursuant to the Registration Statement and shall sell its Registrable Securities in accordance with the Plan of Distribution set forth in the Prospectus. Each Investor further agrees that, upon receipt
of a notice from the Company of the occurrence of any event of the kind described in Sections 6.2(c)(iv) (with respect to a request for an amendment), (v), (vi) or (vii), such Investor will discontinue disposition of
such Registrable Securities under the Registration Statement until such Investor is advised in writing by the Company that the use of the Prospectus, or amended Prospectus, as applicable, may be used. The Company may provide appropriate stop orders
to the Transfer Agent to enforce the provisions of this Section 6.5 and Section 6.1(e). 
 6.6 No Piggyback on
Registrations. Except as set forth on Schedule 6.7, neither the Company nor any of its security holders (other than the Investors in such capacity pursuant hereto) may include securities of the Company in the Registration Statement other
than the Registrable Securities. 
 6.7 Piggy-Back Registrations. If at any time during the Effectiveness Period there is not an
effective Registration Statement covering all of the Registrable Securities and the Company shall determine to prepare and file with the SEC a registration statement relating to an offering for its own account or the account of others under the
Securities Act of any of its equity securities, other than on Form S-4 or Form S-8 (each as promulgated under the Securities Act) or their then equivalents relating to equity securities to be issued solely in connection with any acquisition of any
entity or business or equity securities issuable in connection with stock option or other employee benefit plans, then the Company shall send to each Investor not then eligible to sell all of their Registrable Securities under Rule 144 in a
three-month period, written notice of such determination and if, within ten days after receipt of such notice, any such Investor shall so request in writing, the Company shall include in such registration statement all or any part of such
Registrable Securities such Investor requests to be registered. Notwithstanding the foregoing, in the event that, in connection with any underwritten public offering, the managing underwriter(s) thereof shall impose a limitation on the number of
shares of Common Stock which may be included in the Registration Statement because, in such underwriter(s)’ judgment, marketing or other factors dictate such limitation is necessary to facilitate public distribution, then the Company shall be
obligated to include in such Registration Statement only such limited portion of the Registrable Securities with respect to which such Investor has requested inclusion hereunder as the underwriter shall advise; provided, however, that
(i) the Company shall not exclude any Registrable Securities unless the Company has first excluded all outstanding securities, the holders of which are not contractually entitled to inclusion of such securities in such Registration Statement or
are not contractually entitled to pro rata inclusion with the Registrable Securities and (ii) after giving effect to the immediately preceding proviso, any such exclusion of Registrable Securities shall be made pro rata among the Investors
seeking to include 

  

 -29- 

 
Registrable Securities and the holders of other securities having the contractual right to inclusion of their securities in such Registration Statement by
reason of demand registration rights, in proportion to the number of Registrable Securities or other securities, as applicable, sought to be included by each such Investor or other holder. If an offering in connection with which an Investor is
entitled to registration under this Section 6.7 is an underwritten offering, then each Investor whose Registrable Securities are included in such Registration Statement shall, unless otherwise agreed by the Company, offer and sell such
Registrable Securities in an underwritten offering using the same underwriter or underwriters and, subject to the provisions of this Agreement, on the same terms and conditions as other shares of Common Stock included in such underwritten offering
and shall enter into an underwriting agreement in a form and substance reasonably satisfactory to the Company and the underwriter or underwriters and such other agreements as shall be required by the underwriter or underwriters. Upon the
effectiveness the registration statement for which piggy-back registration has been provided in this Section 6.7, any Event Payments payable to an Investor whose Common Shares are included in such registration statement shall terminate.

 ARTICLE VII 
 MISCELLANEOUS

 7.1 Termination. This Agreement may be terminated by the Company or any Investor, by written notice to the other parties, if the
Closing has not been consummated by the third Business Day following the date of this Agreement; provided that no such termination will affect the right of any party to sue for any breach by the other party (or parties). 
 7.2 Fees and Expenses. Except as expressly set forth in the Transaction Documents to the contrary, each party shall pay the fees and expenses of
its advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party incident to the negotiation, preparation, execution, delivery and performance of this Agreement. The Company shall pay all Transfer Agent
fees, stamp taxes and other taxes and duties levied in connection with the sale and issuance of the applicable Common Shares. 
 7.3
Entire Agreement. The Transaction Documents, together with the Exhibits and Schedules thereto, contain the entire understanding of the parties with respect to the subject matter hereof and supersede all prior agreements and understandings,
oral or written, with respect to such matters, which the parties acknowledge have been merged into such documents, exhibits and schedules. At or after the Closing, and without further consideration, the Company will execute and deliver to the
Investors such further documents as may be reasonably requested in order to give practical effect to the intention of the parties under the Transaction Documents. 
 7.4 Notices. Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and shall be deemed given and effective on the earliest of (a) the
date of transmission, if such notice or communication is delivered via facsimile or email at the facsimile number or email address specified in this Section prior to 6:30 p.m. (New York City time) on a Trading Day, (b) the next Trading Day
after the date of transmission, if such notice or communication is delivered via facsimile or email at the facsimile number or email address specified in this Section on a day that is not a Trading Day or later than 6:30 p.m. (New York City time) on
any Trading Day, (c) the Trading Day following the date of deposit with a nationally recognized 

  

 -30- 

 
overnight courier service, or (d) upon actual receipt by the party to whom such notice is required to be given. The addresses, facsimile numbers and
email addresses for such notices and communications are those set forth on the signature pages hereof, or such other address or facsimile number as may be designated in writing hereafter, in the same manner, by any such Person. 
 7.5 Amendments; Waivers. No provision of this Agreement may be waived or amended except in a written instrument signed, in the case of an
amendment, by the Company and each of the Investors or, in the case of a waiver, by the party against whom enforcement of any such waiver is sought. No waiver of any default with respect to any provision, condition or requirement of this Agreement
shall be deemed to be a continuing waiver in the future or a waiver of any subsequent default or a waiver of any other provision, condition or requirement hereof, nor shall any delay or omission of either party to exercise any right hereunder in any
manner impair the exercise of any such right. Notwithstanding the foregoing, a waiver or consent to depart from the provisions hereof with respect to a matter that relates exclusively to the rights of Investors under Article VI may be
given by Investors holding at least a majority of the Registrable Securities to which such waiver or consent relates. 
 7.6
Construction. The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect any of the provisions hereof. The language used in this Agreement will be deemed to be the
language chosen by the parties to express their mutual intent, and no rules of strict construction will be applied against any party. 
 7.7
Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and permitted assigns. The Company may not assign this Agreement or any rights or obligations hereunder without the
prior written consent of the Investors. Any Investor may assign its rights under this Agreement to any Person to whom such Investor assigns or transfers any Common Shares, provided (i) such transferor agrees in writing with the transferee or
assignee to assign such rights, and a copy of such agreement is furnished to the Company after such assignment, (ii) the Company is furnished with written notice of (x) the name and address of such transferee or assignee and (y) the
Registrable Securities with respect to which such registration rights are being transferred or assigned, (iii) following such transfer or assignment, the further disposition of such securities by the transferee or assignee is restricted under
the Securities Act and applicable state securities laws, (iv) such transferee agrees in writing to be bound, with respect to the transferred Common Shares, by the provisions hereof that apply to the “Investors” and (v) such
transfer shall have been made in accordance with the applicable requirements of this Agreement and with all laws applicable thereto. 
 7.8
No Third-Party Beneficiaries. This Agreement is intended for the benefit of the parties hereto and their respective successors and permitted assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other Person,
except that each Indemnified Party is an intended third party beneficiary of Section 6.4 and (in each case) may enforce the provisions of such Sections directly against the parties with obligations thereunder. 
 7.9 Governing Law; Venue; Waiver of Jury Trial. ALL QUESTIONS CONCERNING THE CONSTRUCTION, VALIDITY, ENFORCEMENT AND INTERPRETATION OF THIS
AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK. THE COMPANY AND INVESTORS HEREBY 

  

 -31- 

 
IRREVOCABLY SUBMIT TO THE NON-EXCLUSIVE JURISDICTION OF THE STATE AND FEDERAL COURTS SITTING IN THE CITY OF NEW YORK, BOROUGH OF MANHATTAN FOR THE
ADJUDICATION OF ANY DISPUTE BROUGHT BY THE COMPANY OR ANY INVESTOR HEREUNDER, IN CONNECTION HEREWITH OR WITH ANY TRANSACTION CONTEMPLATED HEREBY OR DISCUSSED HEREIN (INCLUDING WITH RESPECT TO THE ENFORCEMENT OF ANY OF THE TRANSACTION DOCUMENTS), AND
HEREBY IRREVOCABLY WAIVE, AND AGREE NOT TO ASSERT IN ANY SUIT, ACTION OR PROCEEDING BROUGHT BY THE COMPANY OR ANY INVESTOR, ANY CLAIM THAT IT IS NOT PERSONALLY SUBJECT TO THE JURISDICTION OF ANY SUCH COURT, OR THAT SUCH SUIT, ACTION OR PROCEEDING IS
IMPROPER. EACH PARTY HEREBY IRREVOCABLY WAIVES PERSONAL SERVICE OF PROCESS AND CONSENTS TO PROCESS BEING SERVED IN ANY SUCH SUIT, ACTION OR PROCEEDING BY MAILING A COPY THEREOF VIA REGISTERED OR CERTIFIED MAIL OR OVERNIGHT DELIVERY (WITH EVIDENCE OF
DELIVERY) TO SUCH PARTY AT THE ADDRESS IN EFFECT FOR NOTICES TO IT UNDER THIS AGREEMENT AND AGREES THAT SUCH SERVICE SHALL CONSTITUTE GOOD AND SUFFICIENT SERVICE OF PROCESS AND NOTICE THEREOF. NOTHING CONTAINED HEREIN SHALL BE DEEMED TO LIMIT IN ANY
WAY ANY RIGHT TO SERVE PROCESS IN ANY MANNER PERMITTED BY LAW. THE COMPANY AND INVESTORS HEREBY WAIVE ALL RIGHTS TO A TRIAL BY JURY. 
 7.10
Survival. The representations and warranties, agreements and covenants contained herein shall survive the Closing. 
 7.11
Execution. This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered
to the other party, it being understood that both parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission or email attachment, such signature shall create a valid and binding obligation of
the party executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or email-attached signature page were an original thereof. 
 7.12 Severability. If any provision of this Agreement is held to be invalid or unenforceable in any respect, the validity and enforceability of
the remaining terms and provisions of this Agreement shall not in any way be affected or impaired thereby and the parties will attempt to agree upon a valid and enforceable provision that is a reasonable substitute therefor, and upon so agreeing,
shall incorporate such substitute provision in this Agreement. 
 7.13 Rescission and Withdrawal Right. Notwithstanding anything to
the contrary contained in (and without limiting any similar provisions of) the Transaction Documents, whenever any Investor exercises a right, election, demand or option owed to such Investor by the Company under a Transaction Document and the
Company does not timely perform its related obligations within the periods therein provided, then, prior to the performance by the Company of the Company’s related obligation, such Investor may rescind or withdraw, in its sole discretion from
time to time upon written notice to the Company, any relevant notice, demand or election in whole or in part without prejudice to its future actions and rights. 
  

 -32- 

 7.14 Replacement of Common Shares. If any certificate or instrument evidencing any Common Shares
is mutilated, lost, stolen or destroyed, the Company shall issue or cause to be issued in exchange and substitution for and upon cancellation thereof, or in lieu of and substitution therefor, a new certificate or instrument, but only upon receipt of
evidence reasonably satisfactory to the Company of such loss, theft or destruction and the execution by the holder thereof of a customary lost certificate affidavit of that fact and an agreement to indemnify and hold harmless the Company for any
losses in connection therewith. The applicants for a new certificate or instrument under such circumstances shall also pay any reasonable third-party costs associated with the issuance of such replacement Common Shares. 
 7.15 Remedies. In addition to being entitled to exercise all rights provided herein or granted by law, including recovery of damages, each of the
Investors and the Company will be entitled to seek specific performance under the Transaction Documents. The parties agree that monetary damages may not be adequate compensation for any loss incurred by reason of any breach of obligations described
in the foregoing sentence and hereby agrees to waive in any action for specific performance of any such obligation the defense that a remedy at law would be adequate. 
 7.16 Payment Set Aside. To the extent that the Company makes a payment or payments to any Investor hereunder or any Investor enforces or exercises its rights hereunder or thereunder, and such payment or
payments or the proceeds of such enforcement or exercise or any part thereof are subsequently invalidated, declared to be fraudulent or preferential, set aside, recovered from, disgorged by or are required to be refunded, repaid or otherwise
restored to the Company by a trustee, receiver or any other Person under any law (including, without limitation, any bankruptcy law, state or federal law, common law or equitable cause of action), then to the extent of any such restoration the
obligation or part thereof originally intended to be satisfied shall be revived and continued in full force and effect as if such payment had not been made or such enforcement or setoff had not occurred. 
 7.17 Adjustments in Share Numbers and Prices. In the event of any stock split, subdivision, dividend or distribution payable in shares of Common
Stock (or other securities or rights convertible into, or entitling the holder thereof to receive directly or indirectly shares of Common Stock), combination or other similar recapitalization or event occurring after the date hereof and prior to the
Closing, each reference in any Transaction Document to a number of shares or a price per share shall be amended to appropriately account for such event. 
 7.18 Independent Nature of Investors’ Obligations and Rights. The obligations of each Investor under any Transaction Document are several and not joint with the obligations of any other Investor, and no
Investor shall be responsible in any way for the performance of the obligations of any other Investor under any Transaction Document. The decision of each Investor to purchase Common Shares pursuant to this Agreement has been made by such Investor
independently of any other Investor and independently of any information, materials, statements or opinions as to the business, affairs, operations, assets, properties, liabilities, results of operations, condition (financial or otherwise) or
prospects of the Company and its Subsidiaries which may have been made or given by any other Investor or by any agent or employee of any other Investor, and no Investor or any of its agents or employees shall have any liability to any other Investor
(or any other Person) relating to or arising from any such information, materials, statements or opinions. Nothing contained herein or in any Transaction Document, and no action taken by any Investor pursuant thereto, shall be deemed 

  

 -33- 

 
to constitute the Investors as a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Investors are in
any way acting in concert or as a group with respect to such obligations or the transactions contemplated by the Transaction Document. Each Investor acknowledges that no other Investor has acted as agent for such Investor in connection with making
its investment hereunder and that no other Investor will be acting as agent of such Investor in connection with monitoring its investment hereunder. Each Investor shall be entitled to independently protect and enforce its rights, including without
limitation the rights arising out of this Agreement or out of the other Transaction Documents, and it shall not be necessary for any other Investor to be joined as an additional party in any proceeding for such purpose. 
 7.19 Exculpation Among Investors. Each Investor acknowledges that it is not relying upon any other person, firm or corporation (including without
limitation any other Investor), other than the Company (to the extent set forth in this Agreement), in deciding to invest and in making its investment in the Company. Each Investor agrees that no other Investor nor the respective controlling
persons, officers, directors, partners, agents or employees of any other Investor shall be liable to such Investor for any losses incurred by such Investor in connection with its investment in the Company. 
 7.20 Like Treatment of Investors. Neither the Company nor any of its affiliates shall, directly or indirectly, pay or cause to be paid any
consideration to any Investor for or as an inducement to, or in connection with solicitation of, any consent, waiver or amendment of any terms or provisions of this Agreement unless such consideration is paid to all Investors bound by such consent,
waiver or amendment, whether or not such Investors so consent, waive or agree to amend. 
 7.21 Acknowledgment Regarding Purchase. The
Company acknowledges that no Investor is acting or has acted as an advisor, agent or fiduciary of the Company (or in any similar capacity) with respect to this Agreement and any advice given by any Investor or any of its respective representatives
in connection with this Agreement is merely incidental to the Investors’ purchase of Common Shares. The Company further represents to each Investor that the Company’s decision to enter into this Agreement has been based solely on the
independent evaluation of the transactions contemplated hereby by the Company and its representatives. 
 [SIGNATURE PAGES TO FOLLOW]

  

 -34- 

 IN WITNESS WHEREOF, the parties hereto have caused this Securities Purchase Agreement to be duly executed
by their respective authorized signatories as of the date first indicated above. 
  

					
		 	ORCHID CELLMARK INC.
			
		 	By:	 	 /s/ Thomas A. Bologna

		 	Name:	 	Thomas A. Bologna
		 	Title:	 	President and Chief Executive Officer
		
		 	Address for Notice:
		
		 	Orchid Cellmark Inc.
		 	4390 US Route One North
		 	Princeton, NJ 08540
		 	Facsimile No.: (609) 750-6405
		 	Telephone No.: (609) 750-2200
		 	Attn: Chief Financial Officer
		
	With copies to:	 	Orchid Cellmark Inc.
		 	4390 US Route One North
		 	Princeton, NJ 08540
		 	Facsimile No.: (609) 750-6405
		 	Telephone No.: (609) 750-2200
		 	Attn: General Counsel
		
	and	 	Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
		 	One Financial Center
		 	Boston, MA 02111
		 	Facsimile No.: (617) 542-2241
		 	Telephone No.: (617) 542-6000
		 	Attn: John J. Cheney, III, Esq.

 COMPANY SIGNATURE PAGE 

 Investor Signature Page 
 By its execution and delivery of this signature page, the undersigned Investor hereby joins in and agrees to be bound by the terms and conditions of the
Securities Purchase Agreement dated as of November 20, 2006 (the “Purchase Agreement”) by and among Orchid Cellmark Inc. and the Investors (as defined therein), as to the number of shares of Common Stock set forth below, and
authorizes this signature page to be attached to the Purchase Agreement or counterparts thereof. 
  

			
	Name of Investor:
	
	LB I Group Inc.
		
	By:	 	 /s/ Jeffrey Ferrell

	Name:	 	Jeffrey Ferrell
	Title:	 	Vice President

			
		
	Address:	 	399 Park Avenue (9th Floor)
		 	New York, NY 10022
		 	c/o William Yelsits
	
	Telephone No.: (212) 526-2431
	Facsimile No.: (646) 758-1630
	Email Address: wyelsits@lehman.com
	Number of Shares: 1,041,566
	Aggregate Purchase Price: $2,999,710.08

 Investor Signature Page 
 By its execution and delivery of this signature page, the undersigned Investor hereby joins in and agrees to be bound by the terms and conditions of the
Securities Purchase Agreement dated as of November 20, 2006 (the “Purchase Agreement”) by and among Orchid Cellmark Inc. and the Investors (as defined therein), as to the number of shares of Common Stock set forth below, and
authorizes this signature page to be attached to the Purchase Agreement or counterparts thereof. 
  

			
	Name of Investor:
	
	Accipiter Life Sciences Fund II (Offshore), Ltd.
		
	By:	 	 /s/ Gabe Hoffman

	Name:	 	Gabe Hoffman
	Title:	 	Director

			
		
	Address:	 	c/o Accipiter Capital Management, LLC
		 	399 Park Avenue, 38th Floor
		 	New York, NY 10022
	
	Telephone No.: 212-705-8700
	Facsimile No.: 212-705-8720
	Email Address: ghoffman@accipitercm.com
	Number of Shares: 505,281
	Aggregate Purchase Price: $1,455,209.28

 Investor Signature Page 
 By its execution and delivery of this signature page, the undersigned Investor hereby joins in and agrees to be bound by the terms and conditions of the
Securities Purchase Agreement dated as of November 20, 2006 (the “Purchase Agreement”) by and among Orchid Cellmark Inc. and the Investors (as defined therein), as to the number of shares of Common Stock set forth below, and
authorizes this signature page to be attached to the Purchase Agreement or counterparts thereof. 
  

			
	Name of Investor:
	
	Accipiter Life Sciences Fund II (QP), Ltd.
		
	By:	 	 /s/ Gabe Hoffman

	Name:	 	Gabe Hoffman
	Title:	 	Managing Member of GP

			
		
	Address:	 	c/o Accipiter Capital Management, LLC
		 	399 Park Avenue, 38th Floor
		 	New York, NY 10022
	
	Telephone No.: 212-705-8700
	Facsimile No.: 212-705-8750
	Email Address: ghoffman@accipitercm.com
	Number of Shares: 314,059
	Aggregate Purchase Price: $904,489.92

 Investor Signature Page 
 By its execution and delivery of this signature page, the undersigned Investor hereby joins in and agrees to be bound by the terms and conditions of the Securities Purchase Agreement dated as of November 20, 2006
(the “Purchase Agreement”) by and among Orchid Cellmark Inc. and the Investors (as defined therein), as to the number of shares of Common Stock set forth below, and authorizes this signature page to be attached to the Purchase Agreement or
counterparts thereof. 
  

			
	Name of Investor:
	
	Accipiter Life Sciences Fund, LP
		
	By:	 	 /s/ Gabe Hoffman

	Name:	 	Gabe Hoffman
	Title:	 	Managing Member of GP

			
		
	Address:	 	c/o Accipiter Capital Management, LLC
		 	399 Park Avenue, 38th Floor
		 	New York, NY 10022
	
	Telephone No.: 212-705-8700
	Facsimile No.: 212-705-8750
	Email Address: ghoffman@accipitercm.com
	Number of Shares: 69,514
	Aggregate Purchase Price: $200,200.32

 Investor Signature Page 
 By its execution and delivery of this signature page, the undersigned Investor hereby joins in and agrees to be bound by the terms and conditions of the
Securities Purchase Agreement dated as of November 20, 2006 (the “Purchase Agreement”) by and among Orchid Cellmark Inc. and the Investors (as defined therein), as to the number of shares of Common Stock set forth below, and
authorizes this signature page to be attached to the Purchase Agreement or counterparts thereof. 
  

			
	Name of Investor:
	
	Accipiter Life Sciences Fund II, LP
		
	By:	 	 /s/ Gabe Hoffman

	Name:	 	Gabe Hoffman
	Title:	 	Managing Member of GP

			
		
	Address:	 	c/o Accipiter Capital Management, LLC
		 	399 Park Avenue, 38th Floor
		 	New York, NY 10022
	
	Telephone No.: 212-705-8700
	Facsimile No.: 212-705-8750
	Email Address: ghoffman@accipitercm.com
	Number of Shares: 51,443
	Aggregate Purchase Price: $148,155.84

 Investor Signature Page 
 By its execution and delivery of this signature page, the undersigned Investor hereby joins in and agrees to be bound by the terms and conditions of the
Securities Purchase Agreement dated as of November 20, 2006 (the “Purchase Agreement”) by and among Orchid Cellmark Inc. and the Investors (as defined therein), as to the number of shares of Common Stock set forth below, and
authorizes this signature page to be attached to the Purchase Agreement or counterparts thereof. 
  

			
	Name of Investor:
	
	Accipiter Life Sciences Fund (Offshore), Ltd.
		
	By:	 	 /s/ Gabe Hoffman

	Name:	 	Gabe Hoffman
	Title:	 	Director

			
		
	Address:	 	c/o Accipiter Capital Management, LLC
		 	399 Park Avenue, 38th Floor
		 	New York, NY 10022
	
	Telephone No.: 212-705-8700
	Facsimile No.: 212-705-8750
	Email Address: ghoffman@accipitercm.com
	Number of Shares: 19,703
	Aggregate Purchase Price: $56,744.64

 Investor Signature Page 
 By its execution and delivery of this signature page, the undersigned Investor hereby joins in and agrees to be bound by the terms and conditions of the
Securities Purchase Agreement dated as of November 20, 2006 (the “Purchase Agreement”) by and among Orchid Cellmark Inc. and the Investors (as defined therein), as to the number of shares of Common Stock set forth below, and
authorizes this signature page to be attached to the Purchase Agreement or counterparts thereof. 
  

			
	Name of Investor:
	
	Potomac Capital Partners LP
		
	By:	 	 /s/ Kenneth Berkow

	Name:	 	Kenneth Berkow
	Title:	 	CFO

			
		
	Address:	 	c/o Potomac Capital Management
		 	825 Third Avenue, 33rd Floor
		 	New York, NY 10022
	
	Telephone No.: 212-521-5115
	Facsimile No.: 212-521-5116
	Email Address: kberkow@potomaccap.com
	Number of Shares: 367,925
	Aggregate Purchase Price: $1,059,624.00

 Investor Signature Page 
 By its execution and delivery of this signature page, the undersigned Investor hereby joins in and agrees to be bound by the terms and conditions of the
Securities Purchase Agreement dated as of November 20, 2006 (the “Purchase Agreement”) by and among Orchid Cellmark Inc. and the Investors (as defined therein), as to the number of shares of Common Stock set forth below, and
authorizes this signature page to be attached to the Purchase Agreement or counterparts thereof. 
  

			
	Name of Investor:
	
	Pleiades Investment Partners-R LP
		
	By:	 	 /s/ Kenneth Berkow

	Name:	 	Kenneth Berkow
	Title:	 	CFO

			
		
	Address:	 	c/o Potomac Capital Management
		 	825 Third Avenue, 33rd Floor
		 	New York, NY 10022
	
	Telephone No.: 212-521-5115
	Facsimile No.: 212-521-5116
	Email Address: kberkow@potomaccap.com
	Number of Shares: 260,500
	Aggregate Purchase Price: $750,240.00

 Investor Signature Page 
 By its execution and delivery of this signature page, the undersigned Investor hereby joins in and agrees to be bound by the terms and conditions of the
Securities Purchase Agreement dated as of November 20, 2006 (the “Purchase Agreement”) by and among Orchid Cellmark Inc. and the Investors (as defined therein), as to the number of shares of Common Stock set forth below, and
authorizes this signature page to be attached to the Purchase Agreement or counterparts thereof. 
  

			
	Name of Investor:
	
	Potomac Capital International Ltd
		
	By:	 	 /s/ Kenneth Berkow

	Name:	 	Kenneth Berkow
	Title:	 	CFO

			
		
	Address:	 	c/o Potomac Capital Management
		 	825 Third Avenue, 33rd Floor
		 	New York, NY 10022
	
	Telephone No.: 212-521-5115
	Facsimile No.: 212-521-5116
	Email Address: kberkow@potomaccap.com
	Number of Shares: 239,630
	Aggregate Purchase Price: $690,134.40

 Investor Signature Page 
 By its execution and delivery of this signature page, the undersigned Investor hereby joins in and agrees to be bound by the terms and conditions of the
Securities Purchase Agreement dated as of November 20, 2006 (the “Purchase Agreement”) by and among Orchid Cellmark Inc. and the Investors (as defined therein), as to the number of shares of Common Stock set forth below, and
authorizes this signature page to be attached to the Purchase Agreement or counterparts thereof. 
  

			
	Name of Investor:
	
	UBS O’Connor LLC FBO
	
	O’Connor Global Convertible Arbitrage Master Ltd.
		
	By:	 	 /s/ George Locasto

	Name:	 	George Locasto
	Title:	 	Managing Director

			
		
	Address:	 	UBS O’Connor LLC
		 	One N. Wacker Drive, 32nd Floor
		 	Chicago, IL 60606
	
	Telephone No.: 312-525-5839
	Facsimile No.: 312-525-6271
	Email Address: jeff.richmond@ubs.com
	Number of Shares: 361,600
	Aggregate Purchase Price: $1,041,408.00

 Investor Signature Page 
 By its execution and delivery of this signature page, the undersigned Investor hereby joins in and agrees to be bound by the terms and conditions of the
Securities Purchase Agreement dated as of November 20, 2006 (the “Purchase Agreement”) by and among Orchid Cellmark Inc. and the Investors (as defined therein), as to the number of shares of Common Stock set forth below, and
authorizes this signature page to be attached to the Purchase Agreement or counterparts thereof. 
  

			
	Name of Investor:
	
	UBS O’Connor LLC FBO
	
	O’Connor PIPES Corporate Strategies Master Ltd.
		
	By:	 	 /s/ George Locasto

	Name:	 	George Locasto
	Title:	 	Managing Director

			
		
	Address:	 	UBS O’Connor LLC
		 	One N. Wacker Drive, 32nd Floor
		 	Chicago, IL 60606
	
	Telephone No.: 312-525-5839
	Facsimile No.: 312-525-6271
	Email Address: jeff.richmond@ubs.com
	Number of Shares: 200,000
	Aggregate Purchase Price: $576,000

 Investor Signature Page 
 By its execution and delivery of this signature page, the undersigned Investor hereby joins in and agrees to be bound by the terms and conditions of the
Securities Purchase Agreement dated as of November 20, 2006 (the “Purchase Agreement”) by and among Orchid Cellmark Inc. and the Investors (as defined therein), as to the number of shares of Common Stock set forth below, and
authorizes this signature page to be attached to the Purchase Agreement or counterparts thereof. 
  

			
	Name of Investor:
	
	UBS O’Connor LLC FBO
	
	O’Connor Global Convertible Arbitrage II Master Ltd.
		
	By:	 	 /s/ George Locasto

	Name:	 	George Locasto
	Title:	 	Managing Director

			
		
	Address:	 	UBS O’Connor LLC
		 	One N. Wacker Drive, 32nd Floor
		 	Chicago, IL 60606
	
	Telephone No.: 312-525-5839
	Facsimile No.: 312-525-6271
	Email Address: jeff.richmond@ubs.com
	Number of Shares: 38,400
	Aggregate Purchase Price: $110,592.00

 Investor Signature Page 
 By its execution and delivery of this signature page, the undersigned Investor hereby joins in and agrees to be bound by the terms and conditions of the
Securities Purchase Agreement dated as of November 20, 2006 (the “Purchase Agreement”) by and among Orchid Cellmark Inc. and the Investors (as defined therein), as to the number of shares of Common Stock set forth below, and
authorizes this signature page to be attached to the Purchase Agreement or counterparts thereof. 
  

			
	Name of Investor:
	
	 Capital Ventures International
  
 by: Heights Capital Management, Inc.
  
 its authorized agent

		
	By:	 	 /s/ Martin Kobinger

	Name:	 	Martin Kobinger
	Title:	 	Investment Manager

			
		
	Address:	 	c/o Heights Capital Management
		 	101 California Street, Suite 3250
		 	San Francisco, CA 94111
	
	Telephone No.: 415-403-6500
	Facsimile No.: 415-403-6525

			
	Email Address:	 	 Martin.Kobinger@sig.com
 Sam.Winer@sig.com

	
	Number of Shares: 300,000
	Aggregate Purchase Price: $864,000

 Investor Signature Page 
 By its execution and delivery of this signature page, the undersigned Investor hereby joins in and agrees to be bound by the terms and conditions of the Securities Purchase Agreement dated as of November 20, 2006
(the “Purchase Agreement”) by and among Orchid Cellmark Inc. and the Investors (as defined therein), as to the number of shares of Common Stock set forth below, and authorizes this signature page to be attached to the Purchase Agreement or
counterparts thereof. 
  

			
	Name of Investor:
	
	Cranshire Capital, L.P.
		
	By:	 	 /s/ Miteley P. Kopine

	Name:	 	Miteley P. Kopine
	Title:	 	President Downeview Capital
		 	The General Partner

  

			
	Address:	 	3100 Dundee Road, Suite 703
		 	Northbrook, IL 60062
	
	Telephone No.: 847-562-9030
	Facsimile No.: 847-562-9031
	Email Address: mkopine@cranshirecapital.com
	Number of Shares: 250,000
	Aggregate Purchase Price: $720,000.00

 Investor Signature Page 
 By its execution and delivery of this signature page, the undersigned Investor hereby joins in and agrees to be bound by the terms and conditions of the
Securities Purchase Agreement dated as of November 20, 2006 (the “Purchase Agreement”) by and among Orchid Cellmark Inc. and the Investors (as defined therein), as to the number of shares of Common Stock set forth below, and
authorizes this signature page to be attached to the Purchase Agreement or counterparts thereof. 
  

			
	Name of Investor:
	
	Iroquois Mgmt Fund Ltd.
		
	By:	 	 /s/ Joshua Silverman

	Name:	 	Joshua Silverman
	Title:	 	Authorized Signatory

  

			
	Address:	 	641 Lexington Ave., 26th Floor
		 	New York, NY 10022
	
	Telephone No.: 212-974-3070
	Facsimile No.: 212-207-3452
	Email Address:
	Number of Shares: 250,000
	Aggregate Purchase Price: $720,000.00

 Investor Signature Page 
 By its execution and delivery of this signature page, the undersigned Investor hereby joins in and agrees to be bound by the terms and conditions of the
Securities Purchase Agreement dated as of November 20, 2006 (the “Purchase Agreement”) by and among Orchid Cellmark Inc. and the Investors (as defined therein), as to the number of shares of Common Stock set forth below, and
authorizes this signature page to be attached to the Purchase Agreement or counterparts thereof. 
  

			
	Name of Investor:
	
	Valesco Healthcare Master Fund, L.P.
		
	 By:
	 	 /s/ Keith Maher

	 Name:
	 	Keith Maher
	 Title:
	 	Portfolio Manager, Valesco Healthcare GP, LLC, general partner of Valesco Healthcare Master Fund, LP

  

			
	Address:	 	787 7th Ave, 48th Floor
		 	New York, NY 10019

			
		
	Telephone No.:	 	212-554-4307
		 	212-554-4211

			
	Facsimile No.: 212-515-4355

			
	Email Address:	 	Kmaher@paramountbio.com;
		 	mdavis@paramountbio.com
	Number of Shares: 86,831
	Aggregate Purchase Price: $250,073.28

 Investor Signature Page 
 By its execution and delivery of this signature page, the undersigned Investor hereby joins in and agrees to be bound by the terms and conditions of the
Securities Purchase Agreement dated as of November 20, 2006 (the “Purchase Agreement”) by and among Orchid Cellmark Inc. and the Investors (as defined therein), as to the number of shares of Common Stock set forth below, and
authorizes this signature page to be attached to the Purchase Agreement or counterparts thereof. 
  

			
	Name of Investor:
	
	Otago Partners, LLC
		
	By:	 	 /s/ Lindsay A. Rosenwald, MD

	Name:	 	Lindsay A. Rosenwald, MD
	Title:	 	Managing Member

  

			
	Address:	 	787 7th Ave, 48th Floor
		 	New York, NY 10019

			
	
	Telephone No.: 212-554-4211
	Facsimile No.: 212-554-4355
	Email Address:	 	Mchill@paramountbio.com;
		 	mdavis@paramountbio.com
	Number of Shares: 66,338
	Aggregate Purchase Price: $191,053.44

 Investor Signature Page 
 By its execution and delivery of this signature page, the undersigned Investor hereby joins in and agrees to be bound by the terms and conditions of the
Securities Purchase Agreement dated as of November 20, 2006 (the “Purchase Agreement”) by and among Orchid Cellmark Inc. and the Investors (as defined therein), as to the number of shares of Common Stock set forth below, and
authorizes this signature page to be attached to the Purchase Agreement or counterparts thereof. 
  

			
	Name of Investor:
	
	Aries Master Fund II
		
	By:	 	 /s/ Lindsay A. Rosenwald, MD

	Name:	 	Lindsay A. Rosenwald, MD
	Title:	 	Chairman, Paramount BioCapital Asset Management Inc, Investment Manager of Aries Master Fund II

  

			
	Address:	 	787 7th Ave, 48th Floor
		 	New York, NY 10019

			
	
	Telephone No.: 212-554-4272
	Facsimile No.: 212-554-4355
	Email Address:	 	mdavis@paramountbio.com
	Number of Shares: 51,230
	Aggregate Purchase Price: $147,542.40

 Investor Signature Page 
 By its execution and delivery of this signature page, the undersigned Investor hereby joins in and agrees to be bound by the terms and conditions of the
Securities Purchase Agreement dated as of November 20, 2006 (the “Purchase Agreement”) by and among Orchid Cellmark Inc. and the Investors (as defined therein), as to the number of shares of Common Stock set forth below, and
authorizes this signature page to be attached to the Purchase Agreement or counterparts thereof. 
  

			
	Name of Investor:
	
	Aries Domestic Fund, I, LP
		
	By:	 	 /s/ Lindsay A. Rosenwald, MD

	Name:	 	Lindsay A. Rosenwald, MD
	Title:	 	Chairman, Paramount BioCapital Asset Management Inc, General Partner of Aries Domestic Fund I, LP

  

			
	Address:	 	787 7th Ave, 48th Floor
		 	New York, NY 10019
	
	Telephone No.: 212-554-4272
	Facsimile No.: 212-554-4355

			
	Email Address:	 	mdavis@paramountbio.com
	Number of Shares: 19,971
	Aggregate Purchase Price: $57,516.48

 Investor Signature Page 
 By its execution and delivery of this signature page, the undersigned Investor hereby joins in and agrees to be bound by the terms and conditions of the
Securities Purchase Agreement dated as of November 20, 2006 (the “Purchase Agreement”) by and among Orchid Cellmark Inc. and the Investors (as defined therein), as to the number of shares of Common Stock set forth below, and
authorizes this signature page to be attached to the Purchase Agreement or counterparts thereof. 
  

			
	Name of Investor:
	
	Aries Domestic Fund II, LP
		
	By:	 	 /s/ Lindsay A. Rosenwald, MD

	Name:	 	Lindsay A. Rosenwald, MD
	Title:	 	Chairman, Paramount BioCapital Asset Management Inc, General Partner of the Aries Domestic Fund II, LP

  

			
	Address:	 	787 7th Ave, 48th Floor
		 	New York, NY 10019

			
	
	Telephone No.: 212-554-4272
	Facsimile No.: 212-554-4355
	Email Address:	 	mdavis@paramountbio.com
	Number of Shares: 15,630
	Aggregate Purchase Price: $45,014.40

 Investor Signature Page 
 By its execution and delivery of this signature page, the undersigned Investor hereby joins in and agrees to be bound by the terms and conditions of the
Securities Purchase Agreement dated as of November 20, 2006 (the “Purchase Agreement”) by and among Orchid Cellmark Inc. and the Investors (as defined therein), as to the number of shares of Common Stock set forth below, and
authorizes this signature page to be attached to the Purchase Agreement or counterparts thereof. 
  

			
	Name of Investor:
	
	Hudson Bay Overseas Fund Ltd
		
	By:	 	 /s/ Yoav Roth

	Name:	 	Yoav Roth
	Title:	 	Principal and Portfolio Manager

  

			
	Address:	 	120 Broadway, 40th Floor
		 	New York, NY 10271

			
	
	Telephone No.: 212-571-1244
	Facsimile No.: 212-571-1279
	Email Address:	 	 yroth@hudsonbaycapital.com
 mlee@hudsonbaycapital.com
 dchiu@hudsonbaycapital.com

	Number of Shares: 104,000
	Aggregate Purchase Price: $299,520.00

  

 Investor Signature Page 
 By its execution and delivery of this signature page, the undersigned Investor hereby joins in and agrees to be bound by the terms and conditions of the
Securities Purchase Agreement dated as of November 20, 2006 (the “Purchase Agreement”) by and among Orchid Cellmark Inc. and the Investors (as defined therein), as to the number of shares of Common Stock set forth below, and
authorizes this signature page to be attached to the Purchase Agreement or counterparts thereof. 
  

			
	Name of Investor:
	
	Hudson Bay Fund LP
		
	By:	 	 /s/ Yoav Roth

	Name:	 	Yoav Roth
	Title:	 	Principal and Portfolio Manager

			
		
	Address:	 	120 Broadway, 40th Floor
		 	New York, NY 10271

			
	
	 Telephone No.: 212-571-1244

	 Facsimile No.: 212-571-1279

	 Email Address:
	 	 yroth@hudsonbaycapital.com
 mlee@hudsonbaycapital.com
 dchiu@hudsonbaycapital.com

	 Number of Shares: 96,000

	 Aggregate Purchase Price: $276,480.00

 Investor Signature Page 
 By its execution and delivery of this signature page, the undersigned Investor hereby joins in and agrees to be bound by the terms and conditions of the
Securities Purchase Agreement dated as of November 20, 2006 (the “Purchase Agreement”) by and among Orchid Cellmark Inc. and the Investors (as defined therein), as to the number of shares of Common Stock set forth below, and
authorizes this signature page to be attached to the Purchase Agreement or counterparts thereof. 
  

			
	Name of Investor:
	
	Truk Opportunity Fund, LLC
	
	 By: Atoll Asset Management, LLC

		
	 By:
	 	 /s/ Stephen Saltzstein

	 Name:
	 	Stephen Saltzstein
	 Title:
	 	Managing Director

  

			
	Address:	 	One East 52nd Street
		 	Sixth Floor
		 	New York, NY 10022

			
	
	 Telephone No.: 212-888-2224

	 Facsimile No.: 212-888-0334

	 Email Address:
	 	ssalt@ramcapital.com
	 Number of Shares: 146,859

	 Aggregate Purchase Price: $422,953.92

 Investor Signature Page 
 By its execution and delivery of this signature page, the undersigned Investor hereby joins in and agrees to be bound by the terms and conditions of the
Securities Purchase Agreement dated as of November 20, 2006 (the “Purchase Agreement”) by and among Orchid Cellmark Inc. and the Investors (as defined therein), as to the number of shares of Common Stock set forth below, and
authorizes this signature page to be attached to the Purchase Agreement or counterparts thereof. 
  

			
	Name of Investor:
	
	Truk International Fund, LP
	
	By: Atoll Asset Management, LLC
		
	 By:
	 	 /s/ Stephen Saltzstein

	 Name:
	 	Stephen Saltzstein
	 Title:
	 	Managing Director

  

			
	Address:	 	One East 52nd Street
		 	Sixth Floor
		 	New York, NY 10022

			
	
	 Telephone No.: 212-888-2224

	 Facsimile No.: 212-888-0334

	 Email Address:
	 	ssalt@ramcapital.com
	 Number of Shares: 18,150

	 Aggregate Purchase Price: $52,272.00

			
	Exhibits:	 	
		
	A	 	Schedule of Investors
		
	B	 	Instruction Sheet for Investors
		
	B-1	 	Stock Certificate Questionnaire
		
	B-2	 	Registration Statement Questionnaire
		
	B-3	 	Investor Certificate for Individual Investor
		
	B-4	 	Investor Certificate for Corporation, Partnership, Limited Liability Company, Trust, Foundation and Joint Investors
		
	C	 	Opinion of Company Corporate Counsel
		
	D	 	Plan of Distribution
		
	E	 	Company Transfer Agent Instructions

 Exhibit A 
 Schedule of Investors 
  

						
	 Investor
	  	Common
Shares	  	Purchase Price
	LB I Group Inc.	  	1,041,566	  	$	2,999,710.08
	Accipiter Life Sciences Fund II (Offshore), Ltd.	  	505,281	  	 	1,455,209.28
	Accipiter Life Sciences Fund II (QP), Ltd.	  	314,059	  	 	904,489.92
	Accipiter Life Sciences Fund, LP	  	69,514	  	 	200,200.32
	Accipiter Life Sciences Fund II, LP	  	51,443	  	 	148,155.84
	Accipiter Life Sciences Fund (Offshore), Ltd.	  	19,703	  	 	56,744.64
	Potomac Capital Partners LP	  	367,925	  	 	1,059,624.00
	Pleiades Investment Partners-R LP	  	260,500	  	 	750,240.00
	Potomac Capital International Ltd	  	239,630	  	 	690,134.40
	UBS O’Connor LLC FBO O’Connor Global Convertible Arbitrage Master Ltd.	  	361,600	  	 	1,041,408.00
	UBS O’Connor LLC FBO O’Connor PIPES Corporate Strategies Master Ltd.	  	200,000	  	 	576,000
	UBS O’Connor LLC FBO O’Connor Global Convertible Arbitrage II Master Ltd.	  	38,400	  	 	110,592.00
	Capital Ventures International	  	300,000	  	 	864,000
	Cranshire Capital, L.P.	  	250,000	  	 	720,000.00
	Iroquois Mgmt Fund Ltd.	  	250,000	  	 	720,000.00
	Valesco Healthcare Master Fund, L.P.	  	86,831	  	 	250,073.28
	Otago Partners, LLC	  	66,338	  	 	191,053.44
	Aries Master Fund II	  	51,230	  	 	147,542.40
	Aries Domestic Fund, I, LP	  	19,971	  	 	57,516.48
	Aries Domestic Fund II, LP	  	15,630	  	 	45,014.40
	Hudson Bay Overseas Fund Ltd	  	104,000	  	 	299,520.00
	Hudson Bay Fund LP	  	96,000	  	 	276,480.00
	Truk Opportunity Fund, LLC	  	146,859	  	 	422,953.92
	Truk International Fund, LP	  	18,150	  	 	52,272.00
		  	 	  	 	 
	TOTAL	  	4,874,630	  	$	14,038,934.40
		  	 	  	 	 

 Exhibit B 
 INSTRUCTION SHEET FOR INVESTOR 
 (to be read in conjunction with the entire Securities Purchase
Agreement) 
  

	A.	Complete the following items in the Securities Purchase Agreement: 

  

	 	1.	Complete and execute the Investor Signature Page. The Agreement must be executed by an individual authorized to bind the Investor. 

  

	 	2.	Exhibit B-1 - Stock Certificate Questionnaire: 

 Provide the information requested by the Stock Certificate Questionnaire; 
  

	 	3.	Exhibit B-2 - Registration Statement Questionnaire: 

 Provide the information requested by the Registration Statement Questionnaire. 
  

	 	4.	Exhibit B-3 /B-4 - Investor Certificate: 

 Provide the
information requested by the Certificate for Individual Investors (B-3) or the Certificate for Corporate, Partnership, Limited Liability Company, Trust, Foundation and Joint Investors (B-4), as applicable. 
  

	 	5.	Return, via facsimile, the signed Securities Purchase Agreement including the properly completed Exhibits B-1 through B-4, to: 

 Facsimile: 
 Telephone: 
 Attn: 
  

	 	6.	After completing instruction number five (5) above, deliver the original signed Securities Purchase Agreement including the properly completed Exhibits B-1 through B-4 to:

 Address: 
 Telephone: 
 Attn: 
  

	B.	Instructions regarding the wire transfer of funds for the purchase of the Common Shares will be telecopied to the Investor by the Company at a later date. 

 Exhibit B-1 
 Orchid Cellmark Inc. 
 STOCK CERTIFICATE QUESTIONNAIRE

  

					
		 	Please provide us with the following information:	  	
			
	1.	 	The exact name that the Common Shares are to be registered in (this is the name that will appear on the stock certificate(s)). You may use a nominee name if appropriate:	  	______________________________________
			
	2.	 	The relationship between the Investor of the Common Shares and the Registered Holder listed in response to item 1 above if not the same:	  	______________________________________
			
	3.	 	The mailing address, telephone and telecopy number and email address of the Registered Holder listed in response to item 1 above:	  	 ______________________________________
  
 ______________________________________
  
 ______________________________________
  
 ______________________________________
  
 ______________________________________

			
	4.	 	The Tax Identification Number of the Registered Holder listed in response to item 1 above:	  	______________________________________

 Exhibit B-2 
 Orchid Cellmark Inc. 
 REGISTRATION STATEMENT QUESTIONNAIRE

 In connection with the Registration Statement, please provide us with the following information regarding the Investor.

 1. Please state your organization’s name exactly as it should appear in the Registration Statement: 
 _____________________________________________________________________________ 
 Except as set forth below, your organization does not hold any equity securities of the Company on behalf of another person or entity. 
 State any exceptions here: 
 _____________________________________________________________________________ 
 2. Address of your organization: 
 ______________________________________________________ 
 ______________________________________________________ 
 Telephone: ____________________________ 
 Fax: __________________________________ 
 Contact Person: _________________________

 3. Have you or your organization had any position, office or other material relationship within the past three years with the Company or its affiliates?
(Include any relationships involving you or your affiliates, officers, directors, or principal equity holders (5% or more) that has held any position or office or has had any other material relationship with the Company (or its predecessors or
affiliates) during the past three years.) 
                 Yes
                        
                No 
 If yes, please indicate the
nature of any such relationship below: 

 4. Are you the beneficial owner of any other securities of the Company? (Include any equity securities that you
beneficially own or have a right to acquire within 60 days after the date hereof, and as to which you have sole voting power, shared voting power, sole investment power or shared investment power.) 
                 Yes
                        
                No 
 If yes, please describe the
nature and amount of such ownership as of a recent date. 
 5. Except as set forth below, you wish that all the shares of the Company’s common stock
beneficially owned by you or that you have the right to acquire from the Company be offered for your account in the Registration Statement. 
 State any exceptions here: 
 6. Have you made or are you aware of any arrangements relating to the distribution of the
shares of the Company pursuant to the Registration Statement? 
                 Yes
                        
                No 
 If yes, please describe the
nature and amount of such arrangements. 

 1. NASD Matters 
 (a) State below whether (i) you or any associate or affiliate of yours are a member of the NASD, a controlling shareholder of an NASD member, a person associated with a
member, a direct or indirect affiliate of a member, or an underwriter or related person with respect to the proposed offering; (ii) you or any associate or affiliate of yours owns any stock or other
securities of any NASD member not purchased in the open market; or (iii) you or any associate or affiliate of yours has made any outstanding subordinated loans to any NASD member. If you are a general or limited
partnership, a no answer asserts that no such relationship exists for you as well as for each of your general or limited partners. 
  

							
		 	 Yes:
 _______
	 	 No:
 _______
	 	

 If “yes,” please identify the NASD member and describe your relationship,
including, in the case of a general or limited partner, the name of the partner: 
 If you answer “no” to Question 7(a), you need
not respond to Question 7(b). 
 (b) State below whether you or any associate or affiliate of yours has been an underwriter, or
a controlling person or member of any investment banking or brokerage firm which has been or might be an underwriter for securities of the Corporation or any affiliate thereof including, but not limited to, the common stock now being
registered. 
  

							
		 	 Yes:
 _______
	 	 No:
 _______
	 	

 If “yes,” please identify the NASD member and describe your relationship,
including, in the case of a general or limited partner, the name of the partner. 

 ACKNOWLEDGEMENT 
 The undersigned hereby agrees to notify the Company promptly of any changes in the foregoing information which should be made as a result of any developments, including the passage of time. The undersigned also agrees
to provide the Company and the Company’s counsel any and all such further information regarding the undersigned promptly upon request in connection with the preparation, filing, amending, and supplementing of the Registration Statement (or any
prospectus contained therein). The undersigned hereby consents to the use of all such information in the Registration Statement. 
 The
undersigned understands and acknowledges that the Company will rely on the information set forth herein for purposes of the preparation and filing of the Registration Statement. 
 The undersigned understands that the undersigned may be subject to serious civil and criminal liabilities if the Registration Statement, when it becomes
effective, either contains an untrue statement of a material fact or omits to state a material fact required to be stated in the Registration Statement or necessary to make the statements in the Registration Statement not misleading. The undersigned
represents and warrants that all information it provides to the Company and its counsel is currently accurate and complete and will be accurate and complete at the time the Registration Statement becomes effective and at all times subsequent
thereto, and agrees during the Effectiveness Period and any additional period in which the undersigned is making sales of Shares under and pursuant to the Registration Statement, and agrees during such periods to notify the Company immediately of
any misstatement of a material fact in the Registration Statement, and of the omission of any material fact necessary to make the statements contained therein not misleading. 
  

							
	 Dated:
	 	  
	 		 	  

		 		 		 	Name
				
		 		 		 	  

		 		 		 	Signature
				
		 		 		 	  

		 		 		 	Name and Title of Signatory

 Exhibit B-3 
 Orchid Cellmark Inc. 
 CERTIFICATE FOR INDIVIDUAL INVESTORS

 If the Investor is an individual, he/she must complete, date and sign this Certificate. 
 CERTIFICATE 
 The undersigned
certifies that the representations and responses below are true and accurate: 
 Please check one below: 
              The Investor is natural person whose individual net worth, or joint net
worth with that person’s spouse, at the time of the Closing exceeds $1,000,000; 
              The Investor is a natural person who had an individual income in excess of $200,000 in each of the two most recent calendar years or joint income with that
person’s spouse in excess of $300,000 in each of those years and who reasonably expects to reach the same income level for the current year. 
  

							
		 	  
	 		 	  

		 	Print Name of Investor	 		 	Signature of Investor
				
		 	  
	 		 	  

		 	Print Name of Spouse
(if funds are to be invested in joint name or are community property)	 		 	Signature of Spouse
(if funds are to be invested in joint name or are community property)

 Exhibit B-4 
 Orchid Cellmark Inc. 
 CERTIFICATE FOR CORPORATE, PARTNERSHIP, LIMITED
LIABILITY COMPANY, 
 TRUST, FOUNDATION AND JOINT INVESTORS 
 If the investor is a corporation, partnership, limited liability company, trust, pension plan, foundation, joint Investor (other than a married couple)
or other entity, an authorized officer, partner, or trustee must complete, date and sign this Certificate. 
 CERTIFICATE

 The undersigned certifies that the representations and responses below are true and accurate: 
 (a) The investor has been duly formed and is validly existing and has full power and authority to invest in the Company. The person signing on behalf of
the undersigned has the authority to execute and deliver the Securities Purchase Agreement on behalf of the Investor and to take other actions with respect thereto. 
 (b) Indicate the form of entity of the undersigned: 
              Limited Partnership 
              General Partnership 
              Limited Liability Company 
              Corporation 
              Revocable Trust (identify each grantor and indicate under what circumstances the trust is revocable by the grantor):
                                        
                                        
                                        
                                        
        
 (Continue on a separate piece of paper, if necessary.) 
              Other type of Trust (indicate type of trust and, for trusts other than
pension trusts, name the grantors and beneficiaries):
                                        
                                        
                                        
                                        
       
                                        
                                        
                                        
                                        
                               
 (Continue on a separate piece of paper, if necessary.) 
              Other form of organization (indicate form of organization
(                                        
                 
                                        
                                        
                                       
                                        
                               ). 

 (c) Indicate the approximate date the undersigned entity was
formed:                        . 
 (d) In order for the Company to offer and sell the Common Shares in conformance with state and federal securities laws, the following information must be obtained regarding your investor status. Please initial each
category applicable to you as an investor in the Company. 
  

			
	_____	  	1. A bank as defined in Section 3(a)(2) of the Securities Act, or any savings and loan association or other institution as defined in Section 3(a)(5)(A) of the Securities Act whether acting
in its individual or fiduciary capacity;
		
	_____	  	2. A broker or dealer registered pursuant to Section 15 of the Securities Exchange Act of 1934;
		
	_____	  	3 An insurance company as defined in Section 2(13) of the Securities Act;
		
	_____	  	4 An investment company registered under the Investment Company Act of 1940 or a business development company as defined in Section 2(a)(48) of that Act;
		
	_____	  	5. . A Small Business Investment Company licensed by the U.S. Small Business Administration under Section 301(c) or (d) of the Small Business Investment Act of 1958;
		
	_____	  	6. A plan established and maintained by a state, its political subdivisions, or any agency or instrumentality of a state or its political subdivisions, for the benefit of its employees, if
such plan has total assets in excess of $5,000,000;
		
	_____	  	7. An employee benefit plan within the meaning of the Employee Retirement Income Security Act of 1974, if the investment decision is made by a plan fiduciary, as defined in Section 3(21) of
such Act, which is either a bank, savings and loan association, insurance company, or registered investment advisor, or if the employee benefit plan has total assets in excess of $5,000,000 or, if a self-directed plan, with investment decisions made
solely by persons that are accredited investors;
		
	_____	  	8. A private business development company as defined in Section 202(a)(22) of the Investment Advisers Act of 1940;
		
	_____	  	9. Any partnership or corporation or any organization described in Section 501(c)(3) of the Internal Revenue Code or similar business trust, not formed for the specific purpose of acquiring
the Common Shares, with total assets in excess of $5,000,000;
		
	_____	  	10. A trust, with total assets in excess of $5,000,000, not formed for the specific purpose of acquiring the Common Shares, whose purchase is directed by a sophisticated person as described
in Rule 506(b)(2)(ii) of the Securities Act;
		
	_____	  	 11. An entity in which all of the equity owners qualify under any of the above subparagraphs. If the undersigned belongs to this investor category
only, list the equity owners of the undersigned, and the investor category which each such equity owner satisfies:    _________________________________________________________________________________________
 (Continue on a separate piece of paper, if necessary.)

 Please set forth in the space provided below the (i) states, if any, in the U.S. in which you
maintained your principal office during the past two years and the dates during which you maintained your office in each state, (ii) state(s), if any, in which you are incorporated or otherwise organized and (iii) state(s), if any, in
which you pay income taxes. 
 ____________________________________________________________________________________ 
 ____________________________________________________________________________________ 
 ____________________________________________________________________________________ 
  

	
	 Dated:                        , 2006

	
	  

	 Print Name of Investor

	
	  

	 Name:

	 Title:

	(Signature and title of authorized officer, partner or trustee)

 SECURITIES DELIVERY INSTRUCTIONS 
 Please instruct us as to where you would like the Common Shares delivered to at Closing: 
  

			
	 Name:
	 	  

			
		
	 Company:
	 	  

			
		
	 Address:
	 	  

			
	
	  
  

		
	 Telephone:
	 	  

			
		
	 Other Special Instructions:
	 	  

	  
  

 Exhibit C 
 OPINION OF COMPANY CORPORATE COUNSEL 
 To: The Investors Listed on Schedule I attached hereto 
 Ladies and Gentlemen: 
 This opinion is being furnished to you
pursuant to Section 2.2(a)(ii) of the Securities Purchase Agreement (the “Agreement”), dated as of November     , 2006, between you and Orchid Cellmark Inc., a Delaware corporation (the
“Company”). We have acted as special counsel to the Company in connection with the Agreement and the transactions contemplated therein. Capitalized terms used herein and not otherwise defined herein shall have the respective
meanings assigned to such terms in the Agreement. 
 In rendering the opinions expressed below, we have examined executed originals or
counterparts of (i) the Transaction Documents, (ii) the Company’s Restated Certificate of Incorporation, as amended to date (the “Certificate of Incorporation”), (iii) the Company’s Second Amended and
Restated Bylaws, as amended to date (the “Bylaws”), (iv) the other documents delivered in connection with the Closing on the date hereof, and (v) such other documents as we have deemed necessary for purposes of this
opinion. 
 Insofar as this opinion relates to certain factual matters, and in the absence of our actual knowledge to the contrary, we have
relied (as to those factual matters but not legal conclusions) upon representations and warranties of the Company, certificates of officers of the Company and of public officials, and certificates delivered to you in connection with the Transaction
Documents and the transactions contemplated thereby. 
 As used herein, any reference to “our knowledge,” “best of our
knowledge,” “of which we have knowledge,” “of which we are aware,” “known to us” or words of similar import, shall mean the conscious awareness of the existence or absence of any facts or other information by any
lawyer in this firm who was involved in representing the Company in connection with the transactions contemplated by the Agreement. Except as expressly set forth in this opinion, we have not undertaken any independent investigation, including,
without limitation, any investigation of corporate, court or other documents or records, to determine the existence or absence of any such facts or other information, and no inference as to our knowledge of the existence or absence of any facts or
other information should be drawn from the fact of our representation of the Company. 
 In rendering the opinions set forth herein, we have
assumed, with your permission and without independent inquiry or investigation, (i) the genuineness of all signatures (other than those of the Company or its officers) on all documents and instruments examined by us, (ii) the authenticity
of all documents submitted to us as originals, and (iii) the conformity to originals of all 

 
documents submitted to us as certified, photostatic or conformed copies, and the authenticity of the originals of such documents. We have also assumed that
each of the parties to the Transaction Documents (other than the Company) had all requisite power and authority and has taken all necessary action (corporate or otherwise) to execute and deliver the Transaction Documents to which it is a party and
to effect the transactions contemplated thereby and that the Transaction Documents constitute the legal, valid and binding obligation of each of such other parties enforceable in accordance with their respective terms. 
 Our opinion contained in paragraph (1) below with respect to the due organization, valid existence and good standing of the Company in the State of
Delaware and the good standing and qualification of the Company to do business in the State of New Jersey is based solely upon certificates to such effect issued as of a recent date by the Secretary of State (or comparable official) of the
applicable jurisdiction. 
 Our opinion contained in paragraph (2) below as to the due organization and good standing of the
Subsidiaries (as defined below) is based solely upon certificates to such effect issued as of a recent date by the Secretary of State (or comparable official) of the applicable jurisdiction. 
 Our opinion contained in paragraph (4) below as to enforceability is subject to the further qualification that such enforceability may be
(i) limited by bankruptcy, insolvency (including, without limitation, fraudulent conveyances and fraudulent transfers), reorganization, moratorium and other similar laws relating to or affecting creditors’ rights generally,
(ii) limited by general equitable principles, including, without limitation, concepts of good faith and fair dealing (regardless of whether such enforceability is considered in a proceeding in equity or at law), (iii) subject to the effect
of any public policy considerations or court decisions which may limit the rights of any person or entity to obtain indemnification, and (iv) subject to the effects of generally applicable rules of law that limit or affect the enforcement of
provisions that purport to require waiver of the obligations of good faith, fair dealing, diligence and reasonableness. In addition, we express no opinion as to whether a federal or state court would give effect to the choice of law provisions set
forth in the Transaction Documents. 
 This opinion is limited to the laws of the Commonwealth of Massachusetts, the General Corporation Law
of the State of Delaware, and the federal laws of the United States of America, and we express no opinions with respect to the law of any other jurisdiction. 
 Based upon the foregoing and subject to the assumptions, limitations, qualifications and exceptions stated herein, we are of the opinion that as of the date hereof: 
  

	 	1.	The Company is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware. The Company has all requisite power and authority, and
all material governmental licenses, authorizations, consents and approvals, required to own and operate its properties and assets and to carry on its business as now conducted. The Company is duly qualified to transact business and is in good
standing as a foreign corporation in the State of New Jersey. 

	 	2.	Each of the following subsidiaries of the Company (the “Subsidiaries”) is duly organized and in good standing under the laws of the jurisdiction set forth below:

  

			
	 Subsidiary
	 	 Jurisdiction of Organization

		
	Lifecodes Corporation	 	Delaware
		
	GeneScreen, Inc.	 	Delaware
		
	Orchid Cellmark ULC	 	Nova Scotia
		
	Orchid Cellmark Ltd.	 	United Kingdom

  

	 	3.	The Company has all requisite corporate power and authority to execute, deliver and perform its obligations under each Transaction Document executed by it, or any of its officers,
to issue, sell and deliver the Common Shares pursuant to the Transaction Documents, and to carry out and perform its obligations under, and to consummate the transactions contemplated by, the Transaction Documents. 

  

	 	4.	All corporate action on the part of the Company, its directors and its stockholders necessary for the authorization, execution and delivery by the Company of the Transaction
Documents, the authorization, issuance, sale and delivery of the Common Shares pursuant to the Agreement, and the consummation by the Company of the transactions contemplated by the Transaction Documents has been duly taken. The Transaction
Documents have been duly and validly executed and delivered by the Company and constitute the legal, valid and binding obligation of the Company, enforceable against the Company in accordance with their terms. 

  

	 	5.	The Common Shares which are being issued on the date hereof pursuant to the Agreement are duly authorized and, when issued against payment therefor in accordance with the provisions
of the Agreement, will be validly issued, fully paid and nonassessable, free and clear of any preemptive right pursuant to the Company’s Certificate of Incorporation or under the provisions of the General Corporation Law of the State of
Delaware. 

  

	 	6.	Assuming (i) the accuracy of the representations of the Investors contained in the Agreement and (ii) compliance by the Investors with the covenants set forth in the
Agreement, the Common Shares may be issued to the Investors without registration under the Securities Act of 1933, as amended. 

  

	 	7.	 The execution, delivery and performance by the Company of, and the compliance by the Company with the terms of, the Transaction Documents, the issuance, sale and
delivery of the Common Shares pursuant to the Agreement do not to our knowledge (a) conflict with or result in a violation of any provision of the Certificate of Incorporation or Bylaws or other similar organizational documents of the Company
or its Subsidiaries, or, to our knowledge, any provision of any law, rule or regulation having applicability to the Company or its Subsidiaries, (b) conflict with, result in a breach of or constitute a default (or an event which with notice or
lapse of time or both would become a default) under, or result in or permit the 

	 	 
termination or modification of, any agreement, instrument, order, writ, judgment or decree known to us to which the Company or its Subsidiaries is a party or
is subject or (c) to our knowledge, result in the creation or imposition of any lien, claim or encumbrance on any of the Company’s or its Subsidiaries’ assets or properties. 

  

	 	8.	No consent, license, permit, waiver, approval or authorization of, or designation, declaration, registration or filing with, any court, governmental or regulatory authority, or
self-regulatory organization, is required in connection with the valid execution, delivery and performance by the Company of the Transaction Documents, or the offer, sale, issuance or delivery of the Common Shares or the consummation of the
transactions contemplated thereby, except for (A) the filing of a Form D with the Securities and Exchange Commission, (B) such as may be required under state securities or Blue Sky laws and (C) such as may be required under the rules
of The Nasdaq Stock Market LLC. 

  

	 	9.	The Company is not required to be registered as an “investment company” within the meaning of the Investment Company Act of 1940, as amended. 

 We express no opinion as to any matter other than as expressly set forth above, and no other opinion is intended to be implied nor may be inferred
herefrom. The opinions expressed herein are given as of the date hereof, and we undertake no obligation hereby and disclaim any obligation to advise you of any change after the date hereof pertaining to any matter referred to herein. The opinion is
rendered solely for your benefit and may not be circulated, quoted, relied upon or otherwise referred to by any other person without our written consent. 

 Exhibit D 
 PLAN OF DISTRIBUTION 
 The selling stockholders may, from time to time, sell any or all of their shares of
common stock on any stock exchange, market or trading facility on which the shares are traded or in private transactions. These sales may be at fixed or negotiated prices. The selling stockholders may use any one or more of the following methods
when selling shares: 
  

	•	 	ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers; 

  

	•	 	block trades in which the broker-dealer will attempt to sell the shares as agent but may position and resell a portion of the block as principal to facilitate the transaction;

  

	•	 	purchases by a broker-dealer as principal and resale by the broker-dealer for its account; 

  

	•	 	an exchange distribution in accordance with the rules of the applicable exchange; 

  

	•	 	privately negotiated transactions; 

  

	•	 	short sales; 

  

	•	 	broker-dealers may agree with the selling stockholders to sell a specified number of such shares at a stipulated price per share; 

  

	•	 	a combination of any such methods of sale; and 

  

	•	 	any other method permitted pursuant to applicable law. 

 The selling stockholders may also sell shares under Rule 144 under the Securities Act, if available, rather than under this prospectus. 
 Broker-dealers engaged by the selling stockholders may arrange for other broker-dealers to participate in sales. Broker-dealers may receive commissions or discounts from the selling stockholders (or, if any broker-dealer acts as agent for
the purchaser of shares, from the purchaser) in amounts to be negotiated. The selling stockholders do not expect these commissions and discounts to exceed what is customary in the types of transactions involved. Any profits on the resale of shares
of common stock by a broker-dealer acting as principal might be deemed to be underwriting discounts or commissions under the Securities Act. Discounts, concessions, commissions and similar selling expenses, if any, attributable to the sale of shares
will be borne by a selling stockholder. The selling stockholders may agree to indemnify any agent, dealer or broker-dealer that participates in transactions involving sales of the shares if liabilities are imposed on that person under the Securities
Act. 

 The selling stockholders may from time to time pledge or grant a security interest in some or all of the
shares of common stock owned by them and, if they default in the performance of their secured obligations, the pledgees or secured parties may offer and sell the shares of common stock from time to time under this prospectus after we have filed a
supplement to this prospectus under Rule 424(b)(3) or other applicable provision of the Securities Act of 1933 supplementing or amending the list of selling stockholders to include the pledgee, transferee or other successors in interest as selling
stockholders under this prospectus. 
 The selling stockholders also may transfer the shares of common stock in other circumstances, in which
case the transferees, pledgees or other successors in interest will be the selling beneficial owners for purposes of this prospectus and may sell the shares of common stock from time to time under this prospectus after we have filed a supplement to
this prospectus under Rule 424(b)(3) or other applicable provision of the Securities Act of 1933 supplementing or amending the list of selling stockholders to include the pledgee, transferee or other successors in interest as selling stockholders
under this prospectus. 
 The selling stockholders and any broker-dealers or agents that are involved in selling the shares of common stock
may be deemed to be “underwriters” within the meaning of the Securities Act in connection with such sales. In such event, any commissions received by such broker-dealers or agents and any profit on the resale of the shares of common stock
purchased by them may be deemed to be underwriting commissions or discounts under the Securities Act. 
 We are required to pay all fees and
expenses incident to the registration of the shares of common stock. We have agreed to indemnify the selling stockholders against certain losses, claims, damages and liabilities, including liabilities under the Securities Act. 
 The selling stockholders have advised us that they have not entered into any agreements, understandings or arrangements with any underwriters or
broker-dealers regarding the sale of their shares of common stock, nor is there an underwriter or coordinating broker acting in connection with a proposed sale of shares of common stock by any selling stockholder. If we are notified by any selling
stockholder that any material arrangement has been entered into with a broker-dealer for the sale of shares of common stock, if required, we will file a supplement to this prospectus. If the selling stockholders use this prospectus for any sale of
the shares of common stock, they will be subject to the prospectus delivery requirements of the Securities Act. 
 The anti-manipulation
rules of Regulation M under the Securities Exchange Act of 1934 may apply to sales of our common stock and activities of the selling stockholders. 

 Exhibit E 
 COMPANY TRANSFER AGENT INSTRUCTIONS 
 American Stock Transfer & Trust Company 
 6201 15th Avenue 
 Brooklyn, NY 11219 
 Attention: 
 Re: Orchid Cellmark Inc. 
 Ladies and Gentlemen:

 Reference is made to that certain Securities Purchase Agreement, dated as of November __, 2006 (the “Agreement”), by and among Orchid
Cellmark Inc., a Delaware corporation (the “Company”), and the investors named on the Schedule of Investors attached thereto (collectively, the “Holders”), pursuant to which the Company is issuing to the Holders
shares (the “Common Shares”) of Common Stock of the Company, par value $.001 per share (the “Common Stock”). 
 This letter shall serve as our irrevocable authorization and direction to you (provided that you are the transfer agent of the Company at such time) to issue shares of Common Stock upon transfer or resale of the Common Shares or upon the
request of a Holder, in each case, in compliance with this paragraph. You acknowledge and agree that so long as you have previously received (a) written confirmation from the Company’s legal counsel that either (i) a registration
statement covering resales of the Common Shares has been declared effective by the Securities and Exchange Commission (the “SEC”) under the Securities Act of 1933, as amended (the “Securities Act”) and that resales
of the Common Shares may be made thereunder, or (ii) sales of the Common Shares may be made in conformity with Rule 144 under the Securities Act (“Rule 144”), (b) if applicable, a copy of such registration
statement, and (c) in the case of clause (a)(i) above, a written request of a Holder to issue new certificates representing the Common Shares without any legend restricting transfer and in the case of clause (a)(ii) above, notice from legal
counsel to the Company or any Holder that a transfer of Common Shares has been effected pursuant to Rule 144, then, unless otherwise required by law, within three (3) business days of your receipt of the notice or request referred to in
clause (c) above and the certificates for shares that are being transferred or reissued, you shall issue the certificates representing the Common Shares so requested (in the case of clause (a)(i) above) to the Holder requesting such issuance or
so sold (in the case of clause (a)(ii) above) to the transferees registered in the names of such transferees, and such certificates shall not bear any legend restricting transfer of the Common Shares thereby and should not be subject to any
stop-transfer restriction. If instructed by a Holder to reissue Common Shares pursuant to this paragraph via the Depository Trust Company’s Deposit/Withdrawal at Custodian, or DWAC system, you are hereby instructed to comply with such request
if (a) you are then participating in The Depository Trust Company’s DWAC system and (b) the Common Shares are then eligible to be included in the DWAC system. 

 A form of written confirmation from the Company’s outside legal counsel to the effect that a
registration statement covering resales of the Common Shares has been declared effective by the SEC under the Securities Act and that Common Shares are freely transferable by the Holders and accordingly may be issued (or reissued, as applicable) and
delivered to the Holders free of all legends restricting transfer is attached hereto as Exhibit I. 
 You need not require
further letters from us or our counsel to effect any future issuance or reissuance of shares of Common Stock to the Holders of contemplated by the Agreement and this letter. This letter shall serve as our standing irrevocable instructions with
regard to this matter. 
 Please be advised that the Holders are relying upon this letter as an inducement to enter into the Agreement and,
accordingly, each Holder is a third party beneficiary to these instructions. 
 Please execute this letter in the space indicated to
acknowledge your agreement to act in accordance with these instructions. Should you have any questions concerning this matter, please contact me at (609) 750-2200. 
  

			
	Very truly yours,
	
	ORCHID CELLMARK INC.
		
	 By:
	 	  

	Name:	 	
	Title:	 	

  

			
	THE FOREGOING INSTRUCTIONS ARE
	 ACKNOWLEDGED AND AGREED TO
 this day of
                    , 2006

	
	AMERICAN STOCK TRANSFER & TRUST COMPANY
		
	By:	 	  

	Name:	 	  

	Title:	 	  

 Enclosures 

 DISCLOSURE SCHEDULES 
 TO THE 
 SECURITIES PURCHASE AGREEMENT 
 BY AND AMONG 
 ORCHID CELLMARK INC. 
 AND THE INVESTORS SET FORTH THEREIN 
 November 20, 2006 
 These Disclosure Schedules are being delivered pursuant to that certain Securities Purchase Agreement dated
November 20, 2006, among Orchid Cellmark Inc. (“Orchid”) and the Investors set forth therein (the “Agreement”). Capitalized terms used herein shall have the meanings ascribed to such terms in the Agreement unless otherwise
defined herein. The inclusion of, or reference to, any item on any schedule herein does not constitute an admission that such item or information is material or meets all criteria set forth in the Agreement for inclusion in such schedule.
Information disclosed in any item of any schedule shall be deemed to be disclosed for all purposes of the Agreement and all other schedules or items thereto to the extent the applicability of such information to the Agreement and such other
schedule(s) or item(s) thereto is reasonably apparent. 

 Schedule 3.1(a) 
 SUBSIDIARIES 
 The Company has the following Material Subsidiaries: 
 Orchid Cellmark Ltd., a company formed under the laws of the United Kingdom and a wholly owned subsidiary of Orchid Cellmark Inc. 
 Lifecodes Corporation, a Delaware corporation and wholly owned subsidiary of Orchid Cellmark Inc. 
 GeneScreen, Inc., a Delaware corporation and wholly owned subsidiary of Orchid Cellmark Inc. 
 Orchid Cellmark ULC, a
company formed under the laws of Nova Scotia and a wholly-owned subsidiary of Lifecodes Corporation. 
  

 2 

 Schedule 3.1(f) 
 CAPITALIZATION 
  

					
	 	  	 Authorized
	  	 Issued and Outstanding

	Common Stock	  	150,000,000	  	 24,507,000 issued and
 24,344,000 outstanding at 9/30/06

			
	Preferred Stock	  	 5,000,000,
 including 1,000,000 of Series A Junior Participating Preferred Stock under Shareholder Rights Plan
	  	0
			
	Common Stock Warrants	  	631,560 shares of Common Stock are reserved for issuance.	  	Warrant rights exercisable for up to 631,560 shares of Common Stock are currently outstanding.
			
	1995 Stock Incentive Plan	  	700,000 shares of Common Stock are reserved for issuance. Awards may no longer be made under this Plan.	  	Options exercisable for up to 291,916 shares of Common Stock are currently outstanding under this Plan.
			
	2005 Stock Plan	  	2,200,000 shares of Common Stock are reserved for issuance.	  	Options exercisable for up to 1,216,878 shares of Common Stock are currently outstanding under this Plan.
			
	Employee Stock Purchase Plan	  	550,000 shares of Common Stock are reserved for issuance.	  	0

 On February 27, 2004, the Company issued approximately 3,158,000 shares of common stock and four-year
warrants to purchase an additional approximately 632,000 shares of common stock in a private placement to 33 investors. The warrants in this transaction contain certain anti-dilution and price adjustment provisions and the issuance and sale of the
Common Shares may obligate the Company to adjust the exercise, conversion, exchange or reset price under these warrants. 
  

 3 

 Schedule 3.1(g) 
 SEC REPORTS; FINANCIAL STATEMENTS 
 None. 
  

 4 

 Schedule 3.1(h) 
 NO MATERIAL CHANGES 
 None. 
  

 5 

 Schedule 3.1(j) 
 COMPLIANCE 
 None. 
  

 6 

 Schedule 3.1(o) 
 LISTING AND MAINTENANCE REQUIREMENTS 
 None. 
  

 7 

 Schedule 3.1(p) 
 REGISTRATION RIGHTS 
 None. 
  

 8 

 Schedule 3.1(q) 
 APPLICATION OF TAKEOVER PROTECTIONS 
 None. 
  

 9 

 Schedule 3.1(t) 
 PATENTS AND TRADEMARKS 
 None. 
  

 10 

 Schedule 3.1(x) 
 INTERNAL ACCOUNTING CONTROLS 
 None. 
  

 11Form of Contribution and Assumption Agreement

 Exhibit 10.1 
 CONTRIBUTION, CONVEYANCE AND ASSUMPTION AGREEMENT 
 This Contribution and Assumption Agreement, dated as of
                    , 2006 (this “Contribution Agreement”), is by and among Atlas America, Inc., a Delaware corporation
(“Atlas America”), Atlas Energy Resources, LLC, a Delaware limited liability company (“Atlas Energy”), and Atlas Energy Operating Company, LLC, a Delaware limited liability company (“Energy
Operating”). The above-named entities are sometimes referred to in this Contribution Agreement each as a “Party” and collectively as the “Parties.” 
 W I T N E S S E T H: 
 WHEREAS, Atlas America currently wholly owns the
subsidiaries listed on Schedule 1 hereto (collectively, the “Subsidiaries”) and the assets described on Schedule 2 hereto (collectively, the “Assets”) representing Atlas America’s natural gas and
oil exploration, development, operation, maintenance and production business (the “Business”); 
 WHEREAS, Atlas America has formed
Atlas Energy pursuant to the Delaware LLC Act for the purpose of acquiring, owning and operating the Business; 
 WHEREAS, in order to accomplish the
objectives and purposes in the preceding recital, the following actions have been taken prior to the date hereof: 
  

	 	1.	 	Atlas Resources, Inc., a Pennsylvania corporation, merged with and into Atlas Resources, LLC, a Pennsylvania limited liability company; 

  

	 	2.	 	Atlas Energy Corporation, an Ohio corporation, merged with and into Atlas Energy Ohio, LLC, an Ohio limited liability company; 

  

	 	3.	 	Viking Resources Corporation, a Pennsylvania corporation, merged with and into Viking Resources, LLC, a Pennsylvania limited liability company; 

  

	 	4.	 	REI-NY, Inc., a Delaware corporation, was converted into REI-NY, LLC, a Delaware limited liability company; 

  

	 	5.	 	Resource Well Services, Inc., a Delaware corporation, was converted into Resource Well Services, LLC, a Delaware limited liability company; 

  

	 	6.	 	AIC, Inc., a Delaware corporation, was converted into AIC, LLC, a Delaware limited liability company; 

  

	 	7.	 	Resource Energy, Inc., a Delaware corporation, was converted into and Resource Energy, LLC, a Delaware limited liability company; 

  

	 	8.	 	Atlas Noble Corp., a Delaware corporation, was converted into Atlas Noble, LLC, a Delaware limited liability company; and 

  

	 	9.	 	Atlas America, Inc., a Pennsylvania corporation, merged with and into Atlas America, LLC, a Pennsylvania limited liability company; 

  

 1 

 WHEREAS, Atlas America and certain of the Subsidiaries are parties to the Gathering Agreement (as defined in
Article I) and Atlas America has agreed to assume certain obligations of those Subsidiaries thereunder; 
 WHEREAS, concurrently with the
consummation of the transactions contemplated hereby, each of the following shall occur: 
  

	 	1.	 	Atlas America will contribute the Assets and its 100% interest in each of the Subsidiaries (the “Equity Interests”) to Energy Operating in exchange for
(a)                      common units (“Common Units”) representing a
      % member interest in Atlas Energy, (b)                      Class A units (the
“Class A Units”), representing a       % member interest in Atlas Energy, (c) the management incentive interests (the “Management Incentive Interests”), and (d) the
right to receive $      , in part as a reimbursement of certain capital expenditures incurred with respect to the Assets and Subsidiaries. 

  

	 	2.	 	Atlas America will transfer to Atlas Energy Management, Inc., a Delaware corporation (“Atlas Management”), all of the Class A Units and the Management
Incentive Interests. 

  

	 	3.	 	In connection with the Offering, the public, through the Underwriters, will contribute $       in cash to Atlas Energy less the
Underwriters’ discounts and commissions of $       (the “Spread”) and a structuring fee of $       in exchange for
                     Common Units, representing a       % member interest in Atlas Energy.

  

	 	4.	 	Atlas Energy will pay transaction expenses pursuant to the transactions contemplated by this Contribution Agreement in the amount of approximately
$       (exclusive of the Spread and the structuring fee), retain $ and distribute the balance of the proceeds from the Offering to Atlas America. 

 WHEREAS, to the extent the Underwriters exercise their over-allotment option to purchase up to
                     Common Units, the Company will use the net proceeds to redeem Common Units from Atlas America; 
 NOW, THEREFORE, in consideration of the mutual covenants, representations, warranties and agreements herein contained, the parties hereto agree as follows:

 ARTICLE I DEFINITIONS 
 Section 1.1 Capitalized
terms used herein and not otherwise defined shall have the meanings ascribed to them below: 
 “APL” means Atlas Pipeline Partners, L.P., a
Delaware limited partnership. 
  

 2 

 “Atlas America Entities” means Atlas America and any Person controlled, directly or indirectly, by Atlas
America, other than Atlas Energy, Energy Operating and any subsidiary of any such Person. 
 “Atlas Energy Group” means Atlas Energy, Energy
Operating and any subsidiary of any such Person, treated as a single consolidated entity. 
 “Authority” means (i) the United States of
America, (ii) any state, province, county, municipality or other governmental subdivision within the United States of America, (iii) any court or any governmental department, commission, board, bureau, agency or other instrumentality of
the United States of America, or of any state, province, county, municipality or other governmental subdivision within the United States of America and (iv) the National Association of Securities Dealers. 
 “Business Day” means any day other than a Saturday, a Sunday or any other day when banks are not open for business generally in the State of Delaware.

 “Closing” means the closing of the transactions contemplated pursuant to this Contribution Agreement. 
 “Closing Date” means the date of Closing. 
 “Delaware LLC Act” means the Limited Liability Company Act of the State of Delaware, as amended and any successor to such act. 
 “Gathering Agreement” means the Master Natural Gas Gathering Agreement dated as of February 2, 2000 among Atlas America, Resource Energy, LLC (formerly Resource Energy, Inc.), Viking Resources, LLC (formerly Viking
Resources Corporation) and APL, as amended from time to time. 
 “Investment Program” means a Person principally engaged in the drilling of
natural gas and oil wells for which Atlas America or any of the Subsidiaries or any of their subsidiaries acts as a general partner, managing partner or manager and the securities of which have been offered and sold to investors. 
 “Offering” means the initial public offering of the Common Units contemplated by the Registration Statement. 
 “Operating Agreement” means the Amended and Restated Operating Agreement of Atlas Energy dated of even date herewith by and among Atlas America, Inc.
and the members party thereto, as amended from time to time. 
 “Person” means an individual, corporation, partnership (limited or general),
limited liability company, trust, joint stock company, unincorporated association or other legal entity. 
 “Registration Statement” means
the registration statement on Form S-1 filed with the U.S. Securities and Exchange Commission by Atlas Energy (File No. 333-136094). 
  

 3 

 “Toxic Tort” means a claim or cause of action arising from personal injury or property damage incurred
by the plaintiff that is alleged to have been caused by exposure to, or contamination by, Hazardous Substances that have been released into the environment by or as a result of the actions or omissions of the defendant. 
 “Underwriters” means those of the underwriting syndicate as referenced in the Underwriting Agreement between UBS Securities LLC, as representative of
the Underwriters, and Atlas Energy, dated as of                     , 2006. 
 ARTICLE II CONTRIBUTION AND DISTRIBUTION TRANSACTIONS 
 Section 2.1 Contribution by Atlas America to Energy
Operating. 
 (a) Contribution. Atlas America hereby grants, contributes, conveys, bargains, assigns,
transfers, sets over and delivers to Energy Operating, its successors and assigns, for its and their own use forever, all right, title and interest of Atlas America in and to all of the Assets and all of the Equity Interests (together with the
Assets, the “Transferred Assets”), subject to all matters contained in the instruments of conveyance covering the Transferred Assets to evidence such contribution and conveyance and to encumbrances that do not materially adversely
affect the value of the Transferred Assets or the ability of the Atlas Energy Group to own and operate the Transferred Assets in substantially the same manner as they were operated immediately prior to the Closing Date, in exchange for
(i)                      Common Units,
(ii)                      Class A Units, (iii) the Management Incentive Interests and (iv) the right to receive
$      , in part as a reimbursement of certain capital expenditures made with respect to the Transferred Assets. 
 TO HAVE AND TO HOLD all of such right, title and interest in the Transferred Assets unto Energy Operating, its successors and assigned, together with all and singular rights and appurtenances thereto in anywise
belonging, subject, however, to the terms and conditions stated in this Agreement, and in such instruments of conveyance forever. 
 (b) Assumed Liabilities. Subject to Section 2.1(c), Energy Operating hereby irrevocably and absolutely assumes, agrees to perform, and when due, pay and discharge, only the obligations and liabilities relating to the Transferred
Assets which accrue on or after the Closing Date and only to the extent such obligations and liabilities are not overdue or delinquent on the Closing Date without regard to any grace period and without the occurrence of any increase in amounts due
(the “Assumed Liabilities”); provided, however, that said assumption and agreement to assume the Assumed Liabilities shall not (i) increase the obligation of Energy Operating with respect to the Assumed
Liabilities beyond that of Atlas America, (ii) waive any valid defense that was available to Atlas America with respect to the Assumed Liabilities or (iii) enlarge any rights or remedies of any third party under any of the Assumed
Liabilities. 
 (c) Prorations. All obligations and liabilities assumed by Energy Operating under this Contribution
Agreement that relate to both periods of time prior to the Closing 

  

 4 

 
Date and periods of time from and after the Closing Date shall be prorated as of the close of business on the Closing Date, whether or not such adjustment
would normally be made as of such time. It is the intention of the Parties that Energy Operating should operate the Business and the Transferred Assets for its own account from and after the Closing Date. 
 Section 2.2 General Provisions Relating to Assumption of Liabilities. Notwithstanding anything to the contrary contained in this Agreement including,
without limitation, the terms and provisions of this Article II, none of the Parties shall be deemed to have assumed, and none of the Transferred Assets have been or are being contributed subject to, (a) any liens or security interests securing
consensual indebtedness covering any of the Transferred Assets, except for permitted encumbrances, and all such liens and security interests shall be deemed to be excluded from the assumptions of liabilities made under this Article II or
(b) any of the liabilities covered by the indemnities set forth in this Contribution Agreement to the extent such liabilities are covered by such indemnities, and all such liabilities shall be deemed to be excluded from the assumptions of
liabilities made under this Article II to the extent that such liabilities are covered by such indemnities. 
 Section 2.3 Public Cash
Contribution. The Parties acknowledge a capital contribution by the public through the Underwriters to Atlas Energy of $       in cash, ($       after the
Spread of $       and $       after the payment of the structuring fee of $      ) in exchange for
             Common Units. 
 Section 2.4 Specific Conveyances. To
further evidence the contributions and conveyances of the Transferred Assets, each party making such contribution and conveyances may have executed and delivered to the party receiving such contribution certain conveyance, assignment and bill of
sale instruments (the “Specific Conveyances”). The Specific Conveyances shall evidence and perfect such sale and contribution made by this Contribution Agreement and shall not constitute a second conveyance of any assets or
interests therein and shall be subject to the terms of this Contribution Agreement. 
 Section 2.5 Payment of Transaction Expenses by Atlas
Energy. The Parties acknowledge (a) the payment by Atlas Energy, in connection with the transactions contemplated hereby, of estimated transaction expenses in the amount of $       (exclusive
of the Spread and the structuring fee) and (b) the distribution by Atlas Energy of $       to Atlas America, in part as a reimbursement of certain capital expenditures incurred with respect to the
Transferred Assets. 
 Section 2.6 Issuance of New Certificates. At the Closing, Atlas Energy shall issue to each of Atlas America
and Atlas Management a certificate or certificates, which may be held in book entry form, representing the number of Common Units and Class A Units to be issued to each of them pursuant to the recitals above. Each such certificate shall be
registered in the name of the Person or Persons specified by the recipient thereof to Atlas Energy in writing at least two Business Days prior to the Closing. 
  

 5 

 Section 2.7 Certificate Legends. The certificates evidencing the Common Units and Class A
Units shall bear a legend substantially in the form set forth below and containing such other information as Atlas Energy may deem necessary or appropriate: 
 THE SECURITIES REPRESENTED HEREBY HAVE NOT
BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY
STATE SECURITIES LAWS, AND NEITHER THE SECURITIES NOR ANY INTEREST THEREIN
MAY BE OFFERED, SOLD, TRANSFERRED, PLEDGED OR OTHERWISE DISPOSED OF EXCEPT
PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER SUCH ACT AND SUCH
LAWS OR PURSUANT TO AN EXEMPTION THEREFROM WHICH, IN THE OPINION OF
COUNSEL FOR THE HOLDER, WHICH COUNSEL AND OPINION ARE REASONABLY SATISFACTORY
TO COUNSEL FOR THIS COMPANY, IS AVAILABLE. 
 ARTICLE
III GATHERING AGREEMENT 
 Section 3.1 Assumption of Obligations by Atlas America. Atlas America hereby expressly assumes, for
itself and its successors and assigns, the obligations of each member of the Atlas Energy Group, as they may appear, to timely pay gathering fees to APL under Article 7 and 8 of the Gathering Agreement accruing from and after the Closing Date and
agrees to keep, perform and observe all of the covenants and conditions contained therein on the part of the Subsidiaries to be kept, performed and observed from and after the Closing Date. 
 Section 3.2 Assignment by Atlas Energy. Each of Atlas Energy and Energy Operating, on their own behalf and on behalf of the other members of
the Atlas Energy Group, hereby irrevocably assigns, sets over, transfers and conveys to Atlas America all of the right, title and interest of the members of the Atlas Energy Group in and to all of the gathering fees (i) accruing to any of them
from the Investment Programs and (ii) attributable to the production interest of the members of the Atlas Energy Group for gas gathered from and after the Closing Date pursuant to the Gathering Agreement (the “Assigned
Amounts”). Each of Atlas Energy and Energy Operating shall pay, and shall cause each of the other members of the Atlas Energy Group to pay, the Assigned Amounts to Atlas America within
             Business Days from such entity’s receipt thereof. 
 ARTICLE IV ADDITIONAL
TRANSACTIONS 
 Section 4.1 Over-Allotment Option. The Parties acknowledge that in the event the option to purchase additional
Common Units is exercised in whole or in part by the Underwriters (the “Option”), the public, through the Underwriters, will contribute additional cash to Atlas Energy in exchange for up to an additional
             Common Units. 
 Section 4.2 Redemption of Common Units by Atlas
Energy. The Parties acknowledge, in the event that the Option is exercised in whole or in part by the Underwriters, Atlas Energy will use the net proceeds from the issuance of such additional Common Units to redeem a number of Common
Units from Atlas America equal to the number of Common Units issued pursuant to the exercise of the Option at a redemption price equal to the same net price received by Atlas Energy from the Underwriters. 
  

 6 

 ARTICLE V REPRESENTATIONS AND WARRANTIES 
 Section 5.1 Representations and Warranties of Atlas America. Atlas America hereby represents and warrants to Atlas Energy and Energy Operating as follows as of the date of this Contribution
Agreement: 
 (a) Status of Atlas America. Atlas America has been duly incorporated and is validly existing and in good
standing under the laws of the State of Delaware, with all corporate power and authority necessary to own or hold its properties and conduct the businesses in which it is engaged and to execute and deliver this Contribution Agreement and to
consummate the transactions contemplated hereby. 
 (b) Title to Subsidiaries. Atlas America owns 100% of the issued
and outstanding equity interests in the Subsidiaries; the Subsidiaries own 100% of the issued and outstanding equity interests in their subsidiaries as set forth on Schedule 1; and all such equity interests have been duly authorized and
validly issued in accordance with the charter documents of the relevant entity, and Atlas America and the Subsidiaries own their respective equity interests free and clear of all liens, claims, options, charges, encumbrances or restrictions of any
kind. There are no outstanding warrants, options, agreements, convertible or exchangeable securities, phantom stock or other commitments pursuant to which any Subsidiary or any of their subsidiaries is or may become obligated to issue, sell,
purchase, return or redeem any shares of capital stock or other securities and no equity securities of any Subsidiary or any of their subsidiaries are reserved for issuance for any purpose. 
 (c) Corporate Action/Enforceability. All corporate action required to be taken by Atlas America or any of its securityholders for
the authorization, execution and delivery of this Contribution Agreement and the consummation of the transactions contemplated by this Contribution Agreement have been validly taken. This Contribution Agreement constitutes the valid and binding
obligations of Atlas America, enforceable in accordance with its terms except as such enforceability may be limited by applicable bankruptcy or other similar laws affecting the rights and remedies of creditors generally as well as by general
principles of equity (regardless of whether such enforceability is considered in a proceeding in equity or at law). 
 (d)
Conflicts. None of the (i) the execution, delivery and performance of this Contribution Agreement by Atlas America, or (ii) consummation of the transactions contemplated hereby by Atlas America (A) conflicts or will conflict
with or constitutes or will constitute a violation of Atlas America’s or any member of the Atlas Energy Group’s certificate of incorporation, bylaws or other organizational documents, (B) conflicts or will conflict with or constitutes
or will constitute a breach or violation of, or a default (or an event that, with notice or lapse of time or both, would constitute such a default) under, any indenture, mortgage, deed of trust, loan agreement, lease or other agreement or instrument
to which Atlas America or any member of the Atlas Energy Group is a party or by which Atlas America’s or any member of the Atlas Energy Group’s properties may be bound, (C) violates or will violate any statute, law or regulation or
any order, 

  

 7 

 
judgment, decree or injunction of any Authority having jurisdiction over Atlas America or any member of the Atlas Energy Group or any of their respective
properties or assets, or (D) results or will result in the creation or imposition of any lien, charge or encumbrance upon any property or assets of Atlas America or any member of the Atlas Energy Group, which conflicts, breaches, violations,
defaults or liens, in the case of clauses (B) or (D), would, individually or in the aggregate, have a material adverse effect on (i) the transactions contemplated hereby or (ii) the ownership and use by any member of the Atlas Energy
Group of the Transferred Assets at or after the Closing Date (a “Material Adverse Effect”). 
 (e)
Consents. No permit, consent, approval, authorization, order, registration, filing or qualification of or with any Authority having jurisdiction over Atlas America, any member of the Atlas Energy Group or any of their respective properties or
by any other third party is required in connection with (i) the execution, delivery and performance of this Contribution Agreement by Atlas America, or (ii) the consummation by Atlas America of the transactions contemplated by this
Contribution Agreement, except for such consents that have been obtained or as to which the lack thereof is not reasonably likely to have a Material Adverse Effect. 
 (f) Title to Property. Upon Closing, one or more members of Atlas Energy Group will have: 
 (i) good and defensible title to the producing oil and gas property interests (including the wells and the working and net revenue
interests attributable thereto) (the “Wells”) of Atlas America included in the reserve report, dated March 31, 2006, included in Registration Statement (the “Reserve Report”), subject only to encumbrances that
do not materially adversely affect the value of such oil and gas property interests or the ability of the Partnership Group to operate such oil and gas property interests in substantially the same manner as they were operated immediately prior to
the Closing Date and (ii) good and defensible title to each oil and gas lease as to which proved undeveloped reserves were assigned in the Reserve Report (the “Leases”), subject only to encumbrances that do not materially
adversely affect the value of the such Lease or, in the event that the Atlas Energy Group does not have good and defensible title to such Lease (each, a “Defective Lease”), then (a) the Atlas Energy Group has good and
defensible title to an oil and gas lease as to which no reserves were indicated therefor in the Reserve Report (each, a “Substitute Lease”), (b) one or more drilling locations have been identified for such Substitute Lease as
of the date hereof, (c) the Atlas Energy Group has a reasonable expectation that it will drill a well on one or more of such drilling locations on the Substitute Lease within the 24 months following the date hereof, (d) the Atlas Energy
Group has a reasonable expectation that the wells expected to be drilled at such locations on the Substitute Lease within such 24-month period are generally comparable in reserve potential to the reserves assigned to such Defective Lease in the
Reserve Report and (e) such Substitute Lease is not and has not been otherwise utilized for purposes of this clause (ii) with respect to another Defective Lease; 
  

 8 

 (ii) good and marketable title in fee to all real property and interests in real property
purported to be owned in fee by any of them other than the Leases and Wells (individually, a “Owned Property”) as set forth on Schedule 5.1(f)(ii); 
 (iii) good title to the leasehold estates in all real property, personal property and interests in such property purported to be leased by
any of them other than the Leases and Wells (individually, a “Leased Property”) as set forth on Schedule 5.1(f)(iii); 
 (iv) good title to all equipment, fixtures and other personal property purported to be owned by any of them other than the Wells; and 
 (v) valid and indefeasible easement rights or fee ownership interests in and to the lands on which any Transferred Asset is located as of
the Closing Date; 
 (in each case) subject only all matters contained in the instruments of conveyance covering the Transferred Assets to
evidence such contribution and conveyance and to encumbrances that do not materially adversely affect the value of the Transferred Assets or the ability of the Atlas Energy Group to own and operate the Transferred Assets in substantially the same
manner as they were operated immediately prior to the Closing Date. Except as would not reasonably be expected to have a Material Adverse Effect, the Leases and all of the leases for the Leased Property are valid and in full force and effect, and
there does not exist any default or event that with notice or lapse of time, or both, would constitute a default by any of Atlas America, or any member of the Atlas Energy Group under any of them, and to the knowledge of Atlas America, there does
not exist any default or event that with notice or lapse of time, or both, would constitute a default by any other party under any of them. 
 (g) Equipment and Improvements. The equipment and improvements located on the Leases (or lands pooled therewith), Owned Property and Leased Property are in compliance with all applicable laws and orders, and
are in reasonable and serviceable condition and repair, normal wear and tear excepted, except for any such non-compliance which would not reasonably be expected to have a Material Adverse Effect. Neither the Owned Property or the Leased Property nor
the use or occupancy thereof by Atlas America or any member of the Atlas Energy Group violates in any way any applicable laws, orders, permits, covenants, conditions and restrictions, whether federal, state, local or, to Atlas America’s
knowledge, private, except for any such violation which would not reasonably be expected to have a Material Adverse Effect. 
 (h) Intellectual Property. Schedule 5.1(h) contains a true and complete list and brief description of all patents, trademarks, service marks, trade names, and copyrights (whether or not such trademarks, trade names, service
marks and copyrights are registered), and all pending applications therefor, if any, owned by any member of the Atlas Energy Group or otherwise included in the Assets or in which any member of the Atlas Energy Group has any rights or licenses. No
other patents, trademarks, trade names, service marks or copyrights are reasonably necessary for the conduct of the Business in substantially the same manner as presently operated. To Atlas America’s 

  

 9 

 
knowledge, there is no infringement or alleged infringement by any person of any such trademark, service mark, trade name, copyright or patent. Neither Atlas
America nor any member of the Atlas Energy Group has received any notice from any person alleging any of them is infringing upon, and, to Atlas America’s knowledge, none of Atlas America or any member of the Atlas Energy Group has infringed and
is not now infringing on, any trademark, service mark, trade name, copyright or patent belonging to any other person. 
 (i)
Compliance with the Laws. Atlas America and the members of the Atlas Energy Group have complied with all, and are not in violation of any, applicable laws, permits and orders (including, any applicable building, zoning, environmental
protection, water use or law, ordinance, or regulation) affecting the ownership or operation of the Business or the Transferred Assets, except for any such non-compliance or violation which would not reasonably be expected to have a Material Adverse
Effect. 
 (j) Environmental. 
 (i) Definitions. For purposes of this Contribution Agreement, the following terms shall have the following meanings: 
 (A) The term “Environmental Law(s)” means each and every law, statute, rule, regulation, order, permit, or similar
requirement of each and every Authority and common law now or hereinafter in effect, pertaining to protection of the environment, including (1) the protection of human health, safety, the environment, natural resources and wildlife or
(2) the management, manufacture, possession, presence, use, generation, transportation, treatment, storage, disposal, Release, threatened Release, abatement, removal, remediation or handling of, or exposure to, any Hazardous Substance,
including without limitation the Superfund Amendments Reauthorization Act and the Resource Conservation and Recovery Act or (3) pollution, including without limitation, as amended, CERCLA, the Solid Waste Disposal Act, 42 U.S.C.
Section 6901 et seq., the Clean Air Act, 42 U.S.C. Section 7401 et seq., the Toxic Substances Control Act, the Oil Pollution Act, the Safe Drinking Water Act, the Hazardous Materials Transportation Act and the Federal Water
Pollution Control Act, 33 U.S.C. Section 1251, et seq. 
 (B) The term “Hazardous Substance”
means any substance which is (1) designated, classified or defined as a hazardous substance, hazardous material, hazardous waste, pollutant or contaminant under any Environmental Laws, (2) a petroleum hydrocarbon, including crude oil or
any fraction thereof, (3) hazardous, toxic, corrosive, flammable, explosive, infectious, radioactive or carcinogenic or (4) regulated pursuant to any Environmental Laws. 
 (C) The term “Release” means any spilling, leaking, pumping, pouring, emitting, emptying, discharging, injecting,
escaping, leaching, dumping, or disposing into the environment (including without limitation the abandonment or discarding of barrels, containers, and other receptacles containing any Hazardous Substance). 
  

 10 

 (ii) Compliance with Environmental Laws. Except as would not reasonably be
expected to have a Material Adverse Effect, Atlas America, with respect to the Assets, and each member of the Atlas Energy Group have been and are in compliance with all applicable Environmental Laws, and there has been and is no liability against
Atlas America or any member of the Atlas Energy Group under any applicable Environmental Laws. None of Atlas America or any member of the Atlas Energy Group has any knowledge of any facts or circumstances concerning any alleged violation or
liability arising under any Environmental Law with respect to the Owned Property, the Leased Property, the Leases (or any lands pooled therewith), the Wells or the Business. 
 (iii) No Release of Hazardous Substances. Except in accordance with applicable Environmental Laws or as would not reasonably be
expected to have a Material Adverse Effect, there has been no Release or threatened Release by any member of the Atlas Energy Group or, with respect to the Assets, Atlas America, or, to Atlas America’s knowledge, by any other person of any
Hazardous Substance existing on, beneath or from the surface, subsurface, ground water, sediment, rivers or other bodies of water associated with the Owned Property, the Leased Property, the Leases (or any lands pooled therewith) or the Wells.

 (iv) Permits. Except as would not reasonably be expected to have a Material Adverse Effect, all permits required by
or issued pursuant to any Environmental Law for the ownership, use or operation of the Owned Property, the Leased Property, the Leases or the Wells by any of Atlas America, or any member of the Atlas Energy Group have been obtained in a timely
manner and are presently maintained in full force and effect. The operations of Atlas America, and any member of the Atlas Energy Group are in material compliance with all terms and conditions of such Permits. None of Atlas America or any member of
the Atlas Energy Group has received any notice or other communication and has any knowledge of any facts or circumstances concerning any alleged violation of any such Permits. 
 (v) No Proceedings. There exists no Order, notice of violation, nor any suit, claim, proceeding, citation, directive, summons,
investigation, information request or other notice pending or, to the knowledge of Atlas America, threatened pursuant to any Environmental Law relating to (A) any of Atlas America’s or any member of the Atlas Energy Group’s ownership,
lease, occupation or use of the Owned Property, the Leased Property, the Leases (or any lands pooled therewith) or the Wells, (B) any alleged violation of, or liability under, any Environmental Law by any of Atlas America or any member of the
Atlas Energy Group, or (C) to Atlas America’s knowledge, the suspected presence, Release or threatened Release of any Hazardous Substance on, under, in or from the surface, subsurface, groundwater, sediment, rivers or other bodies of water
associated with the Owned Property, the Leased Property, the Leases (or lands pooled therewith) or the Wells, nor does there exist any valid basis for any such Order, suit, claim, proceeding, citation, directive, summons investigation, information
request, notice of violation, or other notice. 
  

 11 

 (k) Material Contracts. Excluding any Leases and except as set forth in
Schedule 5.1(k), none of the Atlas Energy Group and, to the knowledge of Atlas America, any other party is in material breach or default of any material contract included within the Transferred Assets, including any material contract of any
of the Atlas Energy Group. 
 (l) No Suspense. Except as set forth in Schedule 5.1(l), to the knowledge of Atlas
America, proceeds from the sale of all oil, condensate and gas produced from the Transferred Assets are being received by a member of the Atlas Energy Group and are not being held in suspense by a third party for any reason. Schedule 5.1(l)
also lists all the amounts held in suspense by Atlas America or any member of the Atlas Energy Group with respect to any oil and gas proceeds attributable to their respective properties and assets. 
 (m) Imbalances. Except as set forth in Schedule 5.1(m), there exists no imbalance regarding production taken or marketed
from any Lease in which any member of the Atlas Energy Group has an interest or which is included in the Assets (or from lands pooled with any such Lease) which could result in (i) a portion of any member of the Atlas Energy Group’s
interest in production therefrom (in the case of any Lease) to be taken or delivered from or after the Closing Date without such entity receiving payment therefor and at the price it would have received absent such imbalance; (ii) any such
entity being obligated to make payment to any person or entity as a result of such imbalance; or (iii) production being shut-in or curtailed from or after the Closing Date due to non-compliance with allowables, production quotas, proration
rules, or similar orders or regulations of Authorities; and no such entity will be obligated, by virtue of any prepayment arrangement, take-or-pay agreement, or similar arrangement, to deliver hydrocarbons produced from the Transferred Assets at
some future time without then receiving full payment therefor. 
 (n) Transfer Restrictions. Except as set forth in
Schedule 5.1(n), there are no preferential rights of purchase that are applicable to the transactions contemplated hereby. 
 (o) Seismic Data. No fees will be due and owing in connection with the transactions contemplated hereby under any agreement covering any seismic records, shot points, field notes, interpretations, and geological and geophysical
information held by Atlas America or any member of the Atlas Energy Group. 
 (p) Plugging and Abandonment Obligations.
Except as set forth in Schedule 5.1(p), there are no Wells located any of the Leases (or lands pooled therewith) in which Atlas America or any member of the Atlas Energy Group has an interest where such entity is currently required by
law or contract to plug and abandoned. 
  

 12 

 (q) Royalties and Rentals. Except for revenues which are being suspended in
accordance with applicable law and except to the extent not reasonably likely to have a Material Adverse Effect, all royalties, excess royalties, overriding royalty interests, net profit interests, production payments, and other interests burdening
production from or attributable to the Transferred Assets have been properly and timely paid. 
 ARTICLE VI FURTHER ASSURANCES 
 Section 6.1 Further Assurances. From time to time from and after the date of this Contribution Agreement, and without any further consideration, the
Parties agree to execute, acknowledge and deliver all such additional deeds, assignments, bills of sale, conveyances, instruments, notices, releases, acquittances and other documents, and will do all such other acts and things, all in accordance
with applicable law, as may be necessary or appropriate (i) more fully to assure that the applicable Parties own all of the properties, rights, titles, interests, estates, remedies, powers and privileges granted by this Contribution Agreement,
or which are intended to be so granted, or (ii) more fully and effectively to vest in the applicable Parties and their respective successors and assigns beneficial and record title to the interests contributed and assigned by this Contribution
Agreement or intended so to be, including the Assets and to more fully and effectively carry out the purposes and intent of this Contribution Agreement. 
 Section 6.2 Other Assurances. From time to time after the date of this Contribution Agreement, and without any further consideration, each of the Parties shall execute, acknowledged and deliver all such additional
instruments, notices and other documents, and will do all such other acts and things, all in accordance with applicable law, as may be necessary or appropriate to more fully and effectively carry out the purposes and intent of this Agreement.
Without limiting the generality of the foregoing, the Parties acknowledge that the Parties have used their good faith efforts to identify all the assets being contributed to the Atlas Energy Group as required in connection with the Offering.
However, it is possible that assets intended to be contributed to the Atlas Energy Group were not identified and therefore are not included in the Assets. It is the express intent of the Parties that the Atlas Energy Group will own all assets
necessary to operate the assets that are identified on Schedule A to this Contribution Agreement and in the Registration Statement. To the extent any assets were not identified but are necessary to the operation of assets that were identified, then
the intent of the Parties is that all such unidentified assets are intended to be conveyed to the appropriate members of the Atlas Energy Group. To the extent such assets are identified at a later date, the Parties shall take the appropriate actions
required in order to convey all such assets to the appropriate members of the Atlas Energy Group. Likewise, to the extent that assets are identified at a later date that were not intended by the Parties to be conveyed as reflected in the
Registration Statement, the Parties shall take the appropriate actions required in order to convey all such assets to the appropriate party. 
 ARTICLE VII
INDEMNIFICATION 
 Section 7.1 Survival of Representations and Warranties. The representations and warranties of Atlas America
contained in Section 5.1 shall survive the Closing; provided that those contained in Section 5.1(f)(i) shall expire three years following the Closing Date; those contained in Section 5.1(b) shall survive indefinitely; and all others
shall expire one year following the Closing Date. 
  

 13 

 Section 7.2 Environmental Indemnification. Atlas America shall indemnify, defend and hold harmless the
Atlas Energy Group for a period of one year after the Closing Date from and against environmental and Toxic Tort losses (including, without limitation, economic losses, diminution in value suffered by third parties, and lost profits), damages,
injuries (including, without limitation, personal injury and death), liabilities, claims, demands, causes of action, judgments, settlements, fines, penalties, costs, and expenses (including, without limitation, court costs and reasonable
attorney’s and expert’s fees) of any and every kind or character, known or unknown, fixed or contingent, suffered or incurred by the Atlas Energy Group or any third party by reason of or arising out of: 
 (a) any violation or correction of violation of Environmental Laws associated with the ownership or operation of the Transferred Assets,
or 
 (b) any event or condition associated with ownership or operation of the Transferred Assets (including, without
limitation, the presence of Hazardous Substances on, under, about or migrating to or from the Transferred Assets or the disposal or release of Hazardous Substances generated by operation of the Transferred Assets at non-Transferred Asset locations)
including, without limitation, (i) the cost and expense of any investigation, assessment, evaluation, monitoring, containment, cleanup, repair, restoration, remediation, or other corrective action required or necessary under Environmental Laws,
(ii) the cost or expense of the preparation and implementation of any closure, remedial, corrective action, or other plans required or necessary under Environmental Laws, and (iii) the cost and expense for any environmental or Toxic Tort
pre-trial, trial, or appellate legal or litigation support work; 
 but only to the extent that such violation complained of under Section 7.2(a) or
such events or conditions included under Section 7.2(b) occurred or existed before the Closing Date (collectively, “Covered Environmental Losses”). 
 Section 7.3 Limitations Regarding Environmental Indemnification. The aggregate liability of Atlas America in respect of all Covered Environmental Losses under Section 7.2 shall not exceed
$25,000,000 and Atlas America will not have any obligation under Section 7.2 until the Covered Environmental Losses of the Atlas Energy Group exceed $500,000. 
 Section 7.4 Indemnification by Atlas America. In addition to and not in limitation of the indemnification provided under Sections 7.2, Atlas America shall indemnify, defend and hold harmless each member of the
Atlas Energy Group and such member’s directors, officers, members, employees and representatives from and against any losses, damages, liabilities, claims, demands, causes of action, judgments, settlements, fines, penalties, costs and expenses
(including court costs and reasonable attorney’s fees and expert’s fees) of any and every kind and character, known or unknown, fixed or contingent, suffered or incurred by the Atlas Energy Group (“Losses”), insofar as
such Losses arise out of or are based upon: 
 (a) a breach of the representations and warranties of Atlas America set forth
in Section 5.1 hereof; 
  

 14 

 (b) the failure of Atlas America to perform its obligations under Section 3.1 after
the Closing Date; 
 (c) currently pending legal actions against the Atlas America and its subsidiaries; and 
 (d) all federal, state and local income tax liabilities attributable to the operation of the Transferred Assets prior to the Closing Date,
including any such income tax liabilities of Atlas America and its subsidiaries that may result from the consummation of the formation transactions for the Atlas Energy Group and the Atlas Management. 
 Section 7.6 Indemnification by Atlas Energy. Atlas Energy and Energy Operating, jointly and severally, shall indemnify, defend and hold
harmless Atlas America and such entity’s directors, officers, members, employees and representatives from and against all Losses (including, without limitation, court costs and reasonable attorney’s and expert’s fees) of any and every
kind or character, known or unknown, fixed or contingent, suffered or incurred by Atlas America insofar as such Losses arise out of or are based upon: 
 (a) the Assumed Liabilities, unless such indemnification would not be permitted under the Operating Agreement; or 
 (b) the failure of Atlas Energy to perform its obligations under Section 3.2 after the Closing Date. 
 Section 7.7 Indemnification Procedure. 
 (a) The indemnified party agrees that within a
reasonable period of time after it becomes aware of facts giving rise to a claim for indemnification under this Article VII, it will provide notice thereof in writing to the indemnifying party, specifying the nature of and specific basis for such
claim. 
 (b) The indemnifying party shall have the right to control, at its sole cost and expense, all aspects of the defense
of (and any counterclaims with respect to) any claims brought against the indemnified party that are covered by the indemnification under this Article VII, including the selection of counsel, determination of whether to appeal any decision of any
Authority and the settling of any such matter or any issues relating thereto; provided, however, that no such settlement shall be entered into without the consent of the indemnified party (which consent shall not be unreasonably withheld), with the
concurrence of the Conflicts Committee of Atlas Energy in the case of the Atlas Energy Group, unless it includes a full release of the indemnified party from such matter or issues, as the case may be. 
 (c) The indemnified party agrees to cooperate fully with the indemnifying party, with respect to (i) its pursuit of insurance
coverage or recoveries with respect to the claims covered by the indemnification and (ii) all aspects of the defense of any claims covered by the indemnification, including the prompt furnishing to the indemnifying party of any correspondence
or other notice relating thereto that the indemnified party may receive, permitting the name of the indemnified party to be utilized in connection with such defense, the making available to the indemnifying party of any files, records or other
information of the 

  

 15 

 
indemnified party that the indemnifying party considers relevant to such defense and the making available to the indemnifying party of any employees,
representatives or agents of the indemnified party; provided, however, that in connection therewith the indemnifying party agrees to use reasonable efforts to minimize the impact thereof on the operations of the indemnified party and further agrees
to maintain the confidentiality of all files, records, and other information furnished by the indemnified party. In no event shall the obligation of the indemnified party to cooperate with the indemnifying party as set forth in the immediately
preceding sentence be construed as imposing upon the indemnified party an obligation to hire and pay for counsel in connection with the defense of any claims covered by the indemnification; provided, however, that the indemnified party may, at its
own option, cost and expense, hire and pay for counsel in connection with any such defense. The indemnifying party agrees to keep any such counsel hired by the indemnified party informed as to the status of any such defense, but the indemnifying
party shall have the right to retain sole control over such defense. 
 (d) The date on which written notification of a claim
for indemnification is received by the indemnifying party shall determine whether such claim is timely made. 
 (e) In
determining the amount of any loss, cost, damage or expense for which a Person is entitled to indemnification under this Agreement, the gross amount of any such indemnification will be reduced by (i) any insurance proceeds realized by the
indemnified Person, and such correlative insurance benefit shall be net of any incremental insurance premiums that become due and payable by the indemnified Person as a result of such claim and (ii) all amounts recovered by the indemnified
Person under contractual indemnities from third Persons. 
 ARTICLE VIII MISCELLANEOUS 
 Section 8.1 Costs. Atlas Energy and Energy Operating shall pay all expenses, fees and costs, including all sales, use and similar taxes arising out of the contributions, conveyances and
deliveries to be made hereunder and shall pay all documentary, filing, recording, transfer, deed, and conveyance taxes and fees required in connection therewith. 
 Section 8.2 Headings; References; Interpretation. All Article and Section headings in this Contribution Agreement are for convenience only and shall not be deemed to control or affect the meaning or construction of
any of the provisions hereof. The words “hereof,” “herein” and “hereunder” and words of similar import, when used in this Contribution Agreement, shall refer to this Contribution Agreement as a whole, including all
Schedules and Exhibits attached hereto, and not to any particular provision of this Contribution Agreement. All personal pronouns used in this Contribution Agreement, whether used in the masculine, feminine or neuter gender, shall include all other
genders, and the singular shall include the plural and vice versa. The use herein of the word “including” following any general statement, term or matter shall not be construed to limit such statement, term or matter to the specific items
or matters set forth immediately following such word or to similar items or matters, whether or not non-limiting language (such as “without limitation”, “but not limited to”, or words of similar import) is used with reference
thereto, but rather shall be deemed to refer to all other items or matters that could reasonably fall within the broadest possible scope of such general statement, term or matter. 
  

 16 

 Section 8.3 Successors and Assigns. The Contribution Agreement shall be binding upon and inure
to the benefit of the Parties and their respective successors and permitted assigns. 
 Section 8.4 No Third Party Rights. The
provisions of this Contribution Agreement are intended to bind the Parties as to each other and are not intended to and do not create rights in any other person or confer upon any other person any benefits, rights or remedies and no person is or is
intended to be a third party beneficiary of any of the provisions of this Contribution Agreement. 
 Section 8.5 Counterparts. This
Contribution Agreement may be executed in any number of counterparts, all of which together shall constitute one agreement binding on the parties hereto. 
 Section 8.6 Governing Law. This Contribution Agreement shall be governed by, and construed in accordance with, the laws of the State of Delaware applicable to contracts made and to be performed wholly within such
state without giving effect to conflict of law principles thereof. 
 Section 8.7 Severability. If any of the provisions of this
Contribution Agreement are held by any court of competent jurisdiction to contravene, or to be invalid under, the laws of any political body having jurisdiction over the subject matter hereof, such contravention or invalidity shall not invalidate
the entire Contribution Agreement. Instead, this Contribution Agreement shall be construed as if it did not contain the particular provision or provisions held to be invalid and an equitable adjustment shall be made and necessary provision added so
as to give effect to the intention of the Parties as expressed in this Contribution Agreement at the time of execution of this Contribution Agreement. 
 Section 8.8 Amendment or Modification. This Contribution Agreement may be amended or modified from time to time only by the written agreement of all the Parties; provided, however, that Atlas Energy may not,
without the prior approval of the Atlas Energy conflicts committee, agree to any amendment or modification that, in the reasonable discretion of Atlas Energy, will adversely affect the holders of Atlas Energy common units. Each such instrument shall
be reduced to writing and shall be designated on its face as an Amendment to this Contribution Agreement. 
 Section 8.9
Integration. This Contribution Agreement and the instruments referenced herein supersede all previous understandings or agreements among the Parties, whether oral or written, with respect to their subject matter. This document and
such instruments contain the entire understanding of the Parties with respect to the subject matter hereof and thereof. No understanding, representation, promise or agreement, whether oral or written, is intended to be or shall be included in or
form part of this Contribution Agreement unless it is contained in a written amendment hereto executed by the parties hereto after the date of this Contribution Agreement. 
  

 17 

 Section 8.10 Deed; Bill of Sale; Assignment. To the extent required and permitted by applicable
law, this Contribution Agreement shall also constitute a “deed,” “bill of sale” or “assignment” of the assets and interests referenced herein. 
 Section 8.11 Other of Completion of Transactions. The transactions provided for in Article II of this Agreement shall be completed on the Closing Date in the following order: 
 First, the transactions provided for in Section 2.1(a) shall be completed in the order set forth therein; and 
 Second, the transactions provided for in Section 2.1(b) shall be completed in the order set forth therein. 
 [signature page follows] 
  

 18 

 IN WITNESS WHEREOF, the parties to this Contribution Agreement have caused it to be duly executed as of the date first
above written. 
  

			
	ATLAS AMERICA, INC.
		
	By:	 	  
		 	Name:
		 	Title:
	
	ATLAS ENERGY RESOURCES, LLC
		
	By:	 	  
		 	Name:
		 	Title:
	
	ATLAS ENERGY OPERATING COMPANY, LLC
		
	By:	 	 Atlas Energy Resources, LLC,
 its sole
member

		
	By:	 	  
		 	Name:
		 	Title:

  

 19 

 SCHEDULE 1 
 Subsidiaries Contributed

 Viking Resources, LLC, a Pennsylvania limited liability company 
 AIC, LLC, a Delaware limited liability company 
 Subsidiaries: 
 Atlas Energy Ohio, LLC, an Ohio limited liability company 
 Atlas Resources, LLC, a Pennsylvania limited liability company 
 Anthem Securities, Inc., a Pennsylvania corporation 
 Resource Energy, LLC, a Delaware
limited liability company 
 Subsidiaries: 
 REI-NY, LLC, a Delaware limited liability company 
 Resource Well Services, LLC, a Delaware limited liability
company 
 Atlas Noble, LLC, a Delaware limited liability company 
 Atlas America, LLC, a Pennsylvania limited liability company 

 SCHEDULE 2 
 Assets Contributed

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00113-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00113-of-00352.parquet"}]]